Part I — Full Reading Version: Product Information Summary

Part I: Product Information Summary

The product information summary sits at the core of the creation guide. It is the foundational material for delivering accurate information about an individual prescription drug to healthcare professionals and for advancing appropriate use. Within the guide's three-part structure (Part I product information summaries, Part II advertisements in professional print journals, Part III other materials), it is also the prototype that the other two parts lean on. The advertising rules in Part II are this part's craft compressed into narrow space, and the materials in Part III are told to "fall back on the spirit of the product information summary when no specific rule exists" precisely because this part serves as the reference point for every other judgment.

01Why the "summary" is the core

The foreword states plainly that the basis of appropriate-use information is the electronic package insert, and that product information summaries and the like complement it. That single word, "complement," fixes the standing of the summary. The original is the approved content; the summary ranks below it. So the summary cannot exceed the scope of approval by even one character. It is a core material that nonetheless never becomes the source text itself — this duality is the first key to reading product information summaries.

Then why is a summary needed at all, on top of the package insert? The insert lays out the legally required items without excess or omission; it is not the place to narrate the development history, the full picture of trial design, or the chain of pharmacological action. Under the constraint of never straying from the fact of approval, the summary re-weaves that background and evidence into a form healthcare professionals can verify. It helps to think of it not as a material that adds facts, but one that arranges the path to those facts.

02Two forms — comprehensive and specific-item

Product information summaries come in two forms: the comprehensive product information summary, which covers the whole picture of the product, and the specific-item product information summary, which narrows to particular items such as the explanation of features, pharmacological action, clinical results, indications, or dosage. The basic points of attention in Chapter 1 apply equally to both forms. Even the specific-item version must follow the Chapter 2 rules that correspond to the items it covers. Narrowing the form does not dilute the principles that must be upheld — that is how it is designed.

The split into two forms is a practical allowance: you may build the material to match the breadth of points you want to convey. But so that "narrowing" does not quietly turn into "dropping the inconvenient parts," Chapter 3 sets out required items for the specific-item version in fine detail.

03The three-chapter structure — foundation, fixed form, limited form

Part I is built from three chapters, each with a different character.

Chapter 1 — Basic points of attention: the foundation that applies to all materials

The handling of scientific evidence, the balance of efficacy and safety, adherence to the scope of approval, isolation of reference information, the ban on exaggeration and misunderstanding, the ban on disparagement, and consistency and updating. Roughly 20 points of attention, plus the handling of figures and tables (data), gather here. Not only product information summaries but every material the guide covers takes this chapter as its starting point. Skip Chapter 1 and jump to individual items, and you easily lose sight of the "why" behind each rule.

Chapter 2 — Comprehensive summary: the fixed form of 16 items

It fixes the items to be recorded at 16, and regulates even their order. It leaves the writer no room to pick and choose, requiring complete recording along a set template. This is also a device against turning the guide into an "answer key." Leave what to include to the writer's discretion, and only the convenient items survive. By fixing even the order, the guide closes that escape route.

Chapter 3 — Specific-item summary: the core you cannot drop even when narrowing

It is a summary narrowed to particular items, yet required items are set out in detail: classification number, name, warnings/contraindications, indications, dosage, adverse reactions, and the date of preparation or revision. On top of complying with Chapters 1 and 2, additional rules unique to the limited version stack up (the post-marketing surveillance mark, the cross-reference to the package insert when consolidating into the DI section, the minimum font size, and so on).

04How the foreword's spirit descends into this part

The foreword serves as the constitution of the whole guide, and its implications are made concrete in the rules of the product information summary. Three pillars in particular run through the detailed provisions of Part I.

Closing off "true but misleading"

The duty not to lie and the duty not to mislead are different things. Even when the data themselves are correct, if the way they are shown forms a mistaken impression, it is a violation. That is exactly why there are restraints on figures and tables: show actual counts rather than graphs or percentages when case numbers are small, do not state a risk reduction rate when there is no significant difference, do not use arrows to emphasize the gap against a comparator. These rules implement "do not mislead," not merely "do not lie."

Implementing balance through structure

If you write efficacy, you write safety with the same weight. The font size for safety is the same as, or larger than, the body text for efficacy. Reference information does not exceed a set proportion of the page. These are not a mindset of "please be mindful of balance" but structural constraints translated into measurable quantities — font size and area. Rather than relying on the reader's conscience, the physical quantity of the page guarantees the balance.

Securing verifiability through structure

Sources, statistical methods, and the date of preparation or revision. By requiring these to always be left in place, the guide keeps the claims in a state where a third party can retrace them later. It is no accident that the last of the 16 items is "date of preparation or revision." Not a flashy prohibition, but the accumulation of the plain discipline of leaving a version behind and enabling verification and recall is what supports a material's trustworthiness.

05Connection to the discipline of science

Much of what a product information summary handles is the results of clinical trials. So the guide's rules are continuous with the discipline of evidence and statistics. Grasp this, and the individual prohibitions reveal themselves not as a mere list of rules but as a translation of the craft of science.

The evidence hierarchy and pre-specification

Meta-analyses and systematic reviews, randomized controlled trials, observational studies, case reports, expert opinion — there is a hierarchy in the strength of evidence. The presence or absence of peer review is the watershed of quality. In vitro and animal results are not connected directly to the clinic, because of differences in species, dose, and system. The guide's requirement to mark animal data with "(animal species)" and in vitro data with "(in vitro)," and not to let them be used as a guarantee of clinical effect, carries this hierarchy into the material's notation.

A significant difference is not clinical significance

A p-value merely expresses the probability of obtaining a difference this large or larger by chance, assuming there is no difference; it says nothing about the magnitude of effect or its clinical value. In a large trial even a tiny difference becomes significant, and conversely the absence of a significant difference does not mean equivalence. A result confirmed in a confirmatory manner on a single, pre-specified primary endpoint carries a completely different weight for conclusions than a nominal p-value pulled out after the fact. The summary's repeated demand to "make clear whether a result is confirmatory or a nominal p-value" exists to keep readers from confusing the two.

06How to walk through this part

The summary's rules are many in number and, at first glance, look like a litany of prohibitions. But follow the order and the logic holds. First grasp the "why" in Chapter 1: take in the underlying ideas of balance, scope of approval, the ban on misunderstanding, and verifiability before anything else. Next read the 16 items of Chapter 2 in their flow — from the development history to features and clinical results (the core of efficacy), through handling and the like, always closing with the main references (the basis) and the date of preparation or revision (the version). Finally, in Chapter 3, check the additional rules unique to the narrowed version.

Looking at the related norms alongside this stabilizes the positioning. The guide is a practical manual that translates the principles of the Fair Advertising Standards and the JPMA Code into "how to build the material," and areas outside its provisions remain governed by these higher norms. What is not in the manual does not mean freedom — the foreword's implication holds here too.

→ Source page: Part I: Product Information Summary

Chapter 1: General Considerations

Chapter 1, "Basic Considerations," is a single chapter within Part I, yet its character differs from the rest. Where Chapter 2 handles the sixteen items of the Comprehensive Product Information Summary and Chapter 3 the narrowed-down version, this chapter sets out the premises that apply equally to every material. Comprehensive or specific-item, journal advertising or any other material — unless the promises made here are met, nothing else can proceed. In the "foundation → I → II → III" descent, this is the ground beneath your feet.

01Seven questions that run through the twenty items

The twenty items of Section 1 are not a scattered list of prohibitions. Pressed to their core, they converge on a few questions: Is it scientifically correct? Are efficacy and safety balanced? Does it stay within the scope of approval? Is reference material kept out of the main line? Is the presentation free of exaggeration? Does it avoid disparaging competitors? Is it aligned with the latest facts? Below, the twenty items are regrouped along these seven axes, descending into the specifics of the detailed rules attached to each.

The reason for going down to the detailed rules is simple. No one objects to "write accurately, fairly, and objectively" as a generality. The problem is that even a well-meaning author has a boundary somewhere that gets crossed unconsciously. The Guide names that boundary at a physical level — the way you quote, the size of the type, the axes of a graph. So this chapter, too, does not stop at generalities; it traces those lines one by one.

02The discipline of quotation — eight lines that keep a guideline undistorted

Item 1 requires content to be "based on scientific grounds, accurate, fair, and objective." It looks like a generality, but the attached detailed rule trains on quotation — above all the quotation of academic diagnostic and treatment guidelines — and draws eight concrete lines. Quotation is, by nature, the act of backing one's own claim with third-party authority, and for that very reason a single choice of excerpt can distort the reader's picture. That is why this item carries the densest detailed rule.

Detailed rule: what to observe when quoting

• Quote verbatim. Quotation from commentary that includes figures and tables must faithfully reflect the guideline's intent.
• Do not quote only the passages favorable to your own drug. When quoting from several places, make the quoted locations explicit so that this is apparent.
• Do not emphasize the parts relevant to your own drug with color or bold type.
• Do not include a guideline that contains off-label statements about your own drug. Where a competitor's off-label statement is included, reproduce it unaltered, annotate that it is off-label, and do not word it so as to recommend off-label content.
• Do not let it become disparagement of competitors or their products.
• Where comparable guidelines exist in Japan and abroad, quote the domestic one in principle. An overseas guideline may be translated, but accurately.

03Balance and the scope of approval — guarded by the physical quantity of type size

Item 2 addresses the balance of efficacy and safety; items 3 and 9, the scope of approval. Both are places where the central idea of the foreword is made concrete — on the page and in approval information respectively.

Detailed rule: balance of efficacy and safety

If you state efficacy in clinical results, you must also state safety. And the safety description must be in type the same size as, or larger than, the body text presenting efficacy. Reaching down to the physical quantity of type size is not a matter of formatting. It is a device to keep the reader's first gaze from being drawn away from safety. The asymmetric obligation — safety information is disclosed even when unfavorable to the company; item 11 goes so far as to require that "important safety information be recorded even if unpublished" — is guaranteed through the design of the page itself.

The scope of approval — not a step beyond, in either efficacy or dosage

Neither efficacy nor dosage may be written outside the approved scope. Conditions that limit the scope (so-called qualifying expressions) must be copied accurately so that the approved indication, including those conditions, is conveyed correctly. Even where dosage says "adjust as appropriate," stay within the explicitly stated range. Electronic media must make content clearly understandable, just as print does. The root of this restraint is one word from the foreword: "supplement." The summary is a document subordinate to the package insert, and to exceed the scope of approval by even a single character is no longer supplementing but departing.

04Quarantining reference information — separating secondary findings, QOL, and pharmacology from the main line

Results obtained secondarily in treatment within the approved scope, and pharmacological actions whose relation to the indication is not sufficiently clear, are kept clearly distinct as "reference information" and not allowed to mislead about the indication. And item 8 draws the line: "reference information" must not be written as a feature/characteristic. The aim is to prevent a secondary finding from looking, in the reader's mind, continuous with the principal indication. The idea is to make the grading of information visible on the page.

Detailed rule: handling daily activity and QOL

Daily activity and QOL are, in principle, treated as reference information. However, where the definition of the evaluation index or score is clear and generalized, it does not fall under reference information — yet even then, no expression may mislead about the efficacy. "Reference information or not" decides not only where the finding sits within the material but also the ceiling on how strongly that finding may be stated.

05The ban on exaggeration and disparagement — closing off the step beyond falsehood

Items 10 through 16 name and foreclose a family of expressions that are not false yet still mislead. The ban on exaggeration is a demand one step beyond the ban on falsehood — it targets techniques that leave a false impression without containing a single lie.

Detailed rule: statements that lead to disparagement

No statement may lead to disparagement of competitors or their products. In clinical comparative trials the line is concrete:

• The control drug's trial results may be presented, but their evaluation or interpretive commentary must not be written.
• Do not write anything emphasizing that a competitor's product was ineffective, insufficiently effective, or not tolerated.
• Do not provide commentary on prior therapy (a competitor's product).
• In the trial outline, record as accurately as possible the drug names used (competitors by generic name), the dosing period, dose, and number of cases.

06Alignment and updating — binding a material that ages the moment it is printed

Items 17 through 20 address the axis of time. For a new drug, write with full regard to the deliberations of the Pharmaceutical Affairs and Food Sanitation Council; where conditions or instructions were attached at approval, keep consistency with the related items. Align the material with the latest package insert, review report, and re-examination/reevaluation results, and where particularly important matters among efficacy, dosage, and the warnings/contraindications precautionary information are revised, promptly revise the summary. And comply, as a matter of course, with related laws such as the Pharmaceutical and Medical Device Act and the Standards for Fair Advertising of Drugs, and with self-imposed norms such as the JPMA Code and JPMA notices.

A material begins to age the moment it is printed. Mandating synchronization with the latest version supports, on the operational side, the foreword's idea of verifiability — keeping the point in time of the information traceable after the fact.

07Section 2, data (figures and tables) — which results may be presented

Section 1 handles words; Section 2 handles numbers and graphs. This is a domain where the discipline of science becomes almost directly the rule, divided into five: reliability, accuracy, statistics, charting, and quotation. First the entrance — reliability, which decides "the range of data you may present."

Detailed rule: securing reliability

• Statistical results may be presented only for a pre-specified analysis with scientific validity. To present primary/secondary endpoints or subgroup analyses, the statistical method must have been stated in the analysis plan.
• For a post-hoc analysis (= an extra analysis thought up only after the trial has ended) where the information is nonetheless important (a result suggesting a risk factor for a serious adverse reaction; a tabulation used as evidence of efficacy in, say, an orphan drug (= a drug for a rare disease with very few patients) where statistical significance is hard to show), state at the head of the relevant results that it is post-hoc and why it is shown, and use restrained wording.
• A meta-analysis (= a method that pools the results of several trials into a single evaluation) must be a systematic review (= a method that gathers the literature comprehensively by a pre-set procedure and evaluates it). Record the search source, search keywords, the number of records identified, the total number of records assessed for eligibility, and the number excluded with reasons.
• When a registration-stage clinical trial is published with a re-analysis different from what the original analysis plan specified, that result is post-hoc even though published, and must not be used.

Detailed rule: accuracy (do not distort)

Do not intentionally distort the underlying information. Do not run various analyses and present only the result convenient to your interpretation. Do not crop the figures and tables of an original paper so as to show only the part favorable to you. It sounds obvious, yet a single choice of graph axis or excerpted interval moves the impression greatly. The principle of closing off the "true but misleading" appears here as the discipline of charting and presentation.

08Section 2, statistics and charting — binding method, limits, and scale

From item 2 onward, the writing of statistics and the making of graphs are specified concretely. To present a statistical result, accompany it with the statistical method and its result (confidence interval, p-value, etc.), and where a significance level other than two-sided 5% is used, state that level too.

Detailed rule: when statistics are recorded

• If you adjusted for covariates (= patient-side conditions that can affect the result, such as age, severity, or medical history; background factors, prognostic factors, etc.) or stratification factors (= factors set in advance as the basis for dividing patients into groups), state them in the results.
• If you used a statistical model without a common name for the test or estimation, state the model formula (= the calculation formula expressing the relationships in the data) in the results.
• If you imputed missing values (= data that could not be measured or are absent) — that is, filled them in by estimation — for tabulation or analysis, record the imputation method in the results.
• Subgroup analyses, being largely exploratory, are limited to those written into the trial plan from the outset and scientifically valid. Where a whole-population analysis exists, present the subgroup result together with the whole-population result.

Mistake what a statistic can and cannot say, and the same number turns into an overreaching conclusion. The Guide requires method and limits side by side precisely to prevent that confusion on the page.

Detailed rule: showing results in graphs and tables

Charting carries concrete lines that close off manipulation of impression.

• When showing numbers, state in a clear place whether they are means, medians, geometric means (= an average taken by multiplication, used for data that move multiplicatively, such as ratios or concentrations), or least-squares estimates (= an estimate computed by a statistical model so as to minimize the scatter).
• When showing the presence or absence of significance in a graph or table, state the statistical method in a clear place.
• Do not merge separately obtained data from differing trial conditions into the same graph or table.
• Do not chart so as to emphasize a difference, such as by altering the vertical or horizontal scale more than necessary.
• In figures comparing against a control (including placebo) or showing before/after, do not use arrows or the like to emphasize the difference. Do not emphasize differences with type size or color either.
• Do not embellish the size of a difference with adjectives that have no basis.

Detailed rule: quotation from original papers

When quoting data from an original paper, record it so the content is conveyed accurately, do not excerpt only the part where the conclusion favors your product, take care not to harm the original's true intent, and state the source. The same thinking as the Section 1 quotation rule (section 02) is repeated once more in the world of data — cropping distorts the picture without changing a single character of the original.

→ Source page: Chapter 1: General Considerations

(1) Scientific basis and citation practice

The first principle Chapter 1 places on the author is that "the content must be accurate, fair, and objective, grounded in scientific evidence." This sounds abstract, but the detailed rules narrow to a single concrete question: how to cite clinical practice guidelines issued by academic societies. Guidelines are the most frequently consulted external authority in clinical practice — which is precisely why the manner of citation is scrutinized.

01"Quote verbatim" — how selection creates distortion

Guidelines bring together diverse patient populations, multiple treatment options, and varying strengths of recommendation into a single document. Extracting only the sentence most favorable to one's own product creates an impression inconsistent with the balance the guideline itself embodies. The detailed rules block this at the outset.

Detailed rule: completeness of quotation and disclosure of source location

• Body text must be quoted verbatim. Paraphrasing or condensing is commentary, not quotation.
• When citing from sections that include figures or explanatory passages, the quotation must faithfully reflect the intent the guideline was expressing.
• Citing only the passages favorable to one's own company is not permitted. When quoting from multiple locations within a single guideline, each location quoted must be identified.

The requirement to "identify each quoted location when drawing from multiple passages" is not a formatting convention. It lets the reader trace which portions of the full guideline the author has drawn upon — the minimum unit for guaranteeing verifiability through structure. Without source attribution, a reader cannot detect selective extraction without consulting the full guideline text.

Detailed rule: prohibition on highlighting through color or bold type

• Sections related to one's own company's product must not be set apart with color or bold typeface.

This rule reflects the recognition that formatting is itself part of the message. Underlining the sentence "Recommended as first-line therapy (generic name of own product)" causes every other option on the same page to recede visually. The text is unchanged; the layout alone rewrites the order of priority. The Guide identifies this as a textbook example of expression that is "factual yet misleading," and prohibits the technique.

02Off-label content: an asymmetric obligation that reverses between own and other companies

Guidelines sometimes contain statements that do not match the current domestic approval status. The handling of off-label content differs sharply depending on whether it involves the author's own product or a competitor's, and the two cases are treated in opposite directions.

The asymmetry has a clear rationale. Carrying a guideline that includes off-label content for one's own product creates the risk of steering clinicians toward unapproved use. Altering a guideline to remove a competitor's off-label content would, however, misrepresent what the guideline actually says. Both outcomes violate "accurate and fair" — but the remedies run in opposite directions.

Detailed rule: the off-label notation

• When a guideline contains off-label content for another company's product, the guideline text is not altered.
• The off-label section carries a note stating that it is off-label.
• The note is a factual disclosure only — it must not become an expression that promotes the off-label use.

The note is a warning to the reader, not an editorial judgment on the guideline. It adds the fact "this is not currently approved domestically" and stops there. Inducing the interpretation "therefore this drug should not be used" from that notation is equally prohibited.

03Domestic priority and the standard of translation — the choice of version is itself part of the evidence

Similar guidelines often exist in both domestic and overseas versions. For the same therapeutic area, recommended grades and patient-selection criteria can differ between the two. The detailed rules place a guideline here as well.

Detailed rule: domestic priority and accuracy of translation

• When comparable guidelines exist domestically and overseas, the domestic version takes precedence as a rule.
• Translating an overseas guideline into Japanese is permitted — provided the translation is accurate. Loose paraphrase or omission does not qualify as "quotation."

The basis for domestic priority is consistency with Japan's approval status and clinical practice context. An overseas guideline's recommendations reflect the patient population, the comparator landscape, and the regulatory assumptions of a different jurisdiction. Importing them without qualification creates room for readers to infer that "the same recommendation applies in Japan" — an inference the guideline was never intended to support.

The demand for translation accuracy follows the same logic. Guideline recommendation strength often hinges on a single auxiliary verb — "should," "may," "consider." Rendering these imprecisely is, in effect, a manipulation of how strong the underlying evidence appears.

→ Source page: (1) Scientific basis and citation practice

(2) Balancing efficacy and safety

When Chapter 1, Section 1(2) states that materials must "balance efficacy and safety," it is not a call for fair-mindedness. It is a structural constraint on design — governing which items appear in which column, and even at what point size they are printed. The rule reaches this far: on the very same page where efficacy figures are displayed, safety information must be present, must be mandatory, and must be printed at a type size that is no smaller.

01Why "balance" is an obligation, not a guideline

Materials for prescription drugs are written by the seller. There is a structural gravitational pull toward putting efficacy first. The Guide recognizes this pull and places a constraint on it — not as a stylistic norm saying "write with balance," but as a conditional obligation: if you show efficacy, you must show safety.

Detailed rule (a) is the core of this. "When clinical results present efficacy findings, safety findings must also be recorded." A clinical results section that shows only efficacy is not permitted. Efficacy and safety must appear together. The rule simultaneously activates, in the most concrete possible column, the foreword's idea of an asymmetric duty — safety-related information is disclosed even when it is unfavorable to the company.

Why call it asymmetric? Efficacy data is something the writer is eager to show. Safety data is sometimes something the writer would prefer not to highlight. Despite this asymmetry of incentive, the Guide does not allow safety to be omitted. By presupposing that asymmetric motivation and encoding "if there is efficacy, safety must accompany it" as a structural rule, omission is foreclosed at the design stage.

02Type size as a physical quantity — keeping the reader's first gaze from bypassing safety

Detailed rule (b) is one of the most concrete provisions in the entire Guide. "The safety entries shall be in a type size equal to or larger than the body text presenting the efficacy results." By specifying point size as a physical quantity, the rule closes the loopholes available through layout.

If the type is smaller, information may exist on the page but never be read. A precautions column packed with fine print loses the competition for the physician's attention against large numbers and readable graphs. Even when every word is accurate, a situation in which safety has been "included" but never "communicated" can arise. The Guide's reference to type size reflects an understanding of exactly that reading risk.

Detailed rule: how safety must be shown in the clinical results column

When efficacy results are presented in a clinical results column, the safety content must include the following: adverse event rates, event names, and case counts shown in comparison with the control drug or placebo; and for serious adverse reactions or those leading to discontinuation, the event names and case counts must be recorded. At no point may the entry conclude with a statement that "there were no serious adverse reactions" — there is a clear line between the factual statement that none occurred and the evaluative conclusion that the drug "is safe." The latter constitutes emphasis of safety, which the Guide prohibits.

At the top of the first page of clinical results, place a note — in a larger point size than the body text — that warnings, contraindications, and so on are on a specified page. Precisely because this is where the eye goes first for efficacy figures, the route to safety information is shown before anything else. The logic is the same as the type-size rule: the page design is engineered to place safety information in view first.

03Disclosing unpublished data — the reach of Section 1(11)

Chapter 1, Section 1(11) takes the balance principle one step further. "Important safety-related information shall be thoroughly verified in-house, and shall be recorded even when the data are unpublished."

The reach of this provision is broad. As a rule, the data carried in product information materials are limited to peer-reviewed original papers or approval-review evaluation materials — the clinical results column is the clearest example of this gate. Yet for important safety information, the obligation to disclose arises even beyond that threshold. If unpublished safety data that the company already holds could affect a physician's prescribing decision, the fact that the data have not yet appeared in a journal is not a sufficient reason to withhold them.

This provision connects to the verifiability pillar as well. Information that has not been published cannot be checked from the outside. The Guide requires disclosure anyway because the asymmetric duty to disclose safety information is calibrated not to the existence of external evidence, but to whether the company is aware of the information. The writer is required to "thoroughly verify in-house" before making that judgment — because without the verification step, the disclosure obligation cannot function, and so the verification itself is made an obligation.

→ Source page: (2) Balancing efficacy and safety

(3) Scope of approval

Because the product information summary exists to "supplement" the package insert, everything it contains must be grounded in approved facts. One word beyond the approved scope and the document is no longer a supplement — it is a deviation. Restrictive wording on indications, the ceiling on dosage, and the requirement for equal comprehensibility regardless of medium: these look like three separate rules, but they are all answers to the same question. "Can a healthcare professional understand the approved scope accurately from this material?"

01Restrictive wording — reproducing the approval means copying the condition too

Some indications carry a condition on their use. "Only when [treatment X] is inappropriate," "patients for whom other therapeutic agents have been ineffective" — these phrases are restrictive wording.

Omitting restrictive wording rewrites the approval

What happens when an indication is written in the product information summary without its restrictive wording? The healthcare professional reading it concludes that the indication may be used without conditions. What the package insert approved conditionally appears in the material as unconditional. This is not a reproduction of the approval; it is an alteration of it.

The Guide's requirement that materials be written so that "the approved indication is communicated accurately, including any restrictive wording," follows directly from this. Restrictive wording is not appended to the indication; it is part of the definition of the indication. The same standard applies wherever the indication is mentioned — in the development history column, in the features column, anywhere. When indications differ between overseas and Japan, the domestic approved content must be stated separately, with restrictive wording intact.

Off-label indications — no statement, no suggestion

An unapproved indication may not be stated directly, and it may not be implied or hinted at. Labeling off-label trial results "reference information" does not change this; placed near the indication column, the boundary between approved and unapproved blurs for the reader. When off-label content must appear, the procedure is strict: state at the outset, in prominent text, that the content is partly off-label and give the reason for its inclusion, then annotate the corresponding approved indication and dosage.

02Dosage — "adjust as appropriate" is not a waiver of the ceiling

The same principle runs through dosage. Do not state anything outside the approved dosage range. The phrase most likely to be misread here is "adjust dosage as appropriate."

What "adjust as appropriate" means — and what it does not

When approved dosage instructions include "adjust as appropriate," this permits the prescriber to calibrate the dose to the patient's condition. But the room for adjustment lies within the range the approval document expressly specifies; it is not permission to exceed the stated ceiling. A product information summary may not present efficacy data from doses above the approved maximum, even when adjustment is permitted.

Trial data that are inconsistent with the approved starting dose or the approved method of adjustment may not be used either. If a drug is approved for twice-daily administration and the material presents only the results of a three-times-daily trial, a gap opens between the material and the approved dosage. The reader is left to bridge that gap unaided, and the information has not been "communicated accurately."

Dose-finding trials

A trial that includes off-label dose groups must be labeled "dose-finding trial," with the approved dosage noted. This lets the reader see which part of the data underlies the approval and which lies outside it. The answer is not to hide the data, but to mark its position — that is how the boundary of the approval is preserved.

03Medium neutrality — electronic materials must meet the same standard as paper

When information is provided via electronic medium, it must be prepared so that healthcare professionals understand the content as clearly as they would from paper. This sounds self-evident; in practice it identifies a specific trap.

The latitude that electronic media allow

Electronic materials can expand content on click, nest information in layered menus, and switch displays dynamically. These features are useful for organizing information — but they also make it technically possible to place information that the reader must see without fail, such as restrictive wording or dosage ceilings, behind interactions that the reader might never perform.

The Guide frames this not as a question about the medium but as a question about comprehensibility. If information that is required to be visible on paper ends up in a location that requires navigation to reach, then the electronic material has not functioned as a genuine substitute for paper. "Visible" and "findable with effort" are not the same standard.

The container changes; the quality of supplementation does not

The product information summary is the container through which the package insert is supplemented. When the container changes from paper to electronic, the scope of information it must carry and the quality with which that information reaches healthcare professionals do not change. This connects directly to the foreword's phrase "inform accurately without misleading." Just as rules on point size and framing in print materials address the gap between "included" and "communicated," the medium-neutrality requirement for electronic materials closes the same gap in a different setting.

→ Source page: (3) Scope of approval

(4) Isolation of reference information

The Guide divides clinical trial findings into two tiers: those that constitute the primary evidence for an approved indication, and those that represent incidental, accompanying observations. The second tier carries the label reference information, and the Guide requires that it be recorded with its status explicitly distinguished. The classification is not a housekeeping matter. Where something is placed determines the ceiling on how forcefully it may be communicated — that is the core of the discipline the Guide calls isolation of reference information.

01Secondary results are recorded separately as reference information

When a treatment conducted within the scope of an approved indication produces results that are incidental to the primary objective, those results must be clearly distinguished from the primary evidence of efficacy and recorded as reference information. And regardless of that framing, expression that could cause the reader to misunderstand the approved indication must be avoided.

Secondary findings were not pre-specified as primary endpoints in the trial design. They were observed exploratorily, not confirmed through a hypothesis-testing analysis. Even numbers drawn from the same clinical trial carry fundamentally different evidential weight depending on whether they come from the primary, confirmatory analysis or from a secondary observation. The approved indication rests on the confirmatory analysis of the primary endpoint. Secondary results can only be used in the context of supplementing that approval — no more.

Why the distinction in writing is necessary

Without an explicit distinction, the reader receives primary evidence and secondary findings as equivalent. When a physician makes a prescribing decision, knowing which figure was confirmatory and which was an exploratory observation is directly relevant to interpreting the evidence correctly. Failing to mark the distinction on the page allows the material as a whole to leave an inflated impression of the approved indication. The explicit "reference information" label is the brake on that impression.

02Daily activity and QoL are treated as reference information as a rule

Assessments of activities of daily living (ADL) and quality of life (QoL) are directly relevant to patients' experience of illness, and carry real weight for clinicians. Yet the Guide designates them reference information as a rule.

The reason lies in the nature of the measurement. ADL and QoL assessments reflect the patient's subjective experience and living environment; compared with direct pathophysiological indicators of disease, they carry a wider range of variability and are more susceptible to measurement bias. The principal basis of efficacy in the approval review is generally the core disease symptoms or objective clinical endpoints. Improvement in ADL or QoL may be expected as a downstream consequence, but it is distinct from the approved indication itself.

Detailed rule: when the assessment scale is standardized

The detailed rules carve out one qualification. When the definition of the assessment scale or score is clear and widely established, there are cases in which it does not fall under reference information. Standardized scales — internationally validated functional assessment instruments, for example — have definitions and measurement methods shared across the clinical community, leaving little room for arbitrary interpretation. In such cases the reference-information classification may not apply.

That qualification does not, however, grant an unconditional licence to make stronger claims. Even with a standardized scale, the requirement to avoid expression that could mislead about the approved indication remains in force. Only the evidential standing of the scale changes; the duty to prevent misunderstanding persists.

03Pharmacological actions with unclear relevance to the indication are treated the same way

A pharmacological action whose relevance to the approved indication is not sufficiently established is likewise treated as reference information, in the same way as secondary clinical results.

Descriptions of pharmacological action sit within the material as explanations of the mechanism that underlies the approved indication. Not every pharmacological change observed in a study connects directly to that approved indication. Placing findings of unclear relevance alongside the primary pharmacological data creates the risk of implying that the drug has benefits beyond what was approved. The Guide assigns such findings to the reference-information category and requires that they be presented as knowledge whose relationship to the approved indication has not been established.

04Reference information must not be recorded in the features column

A finding classified as reference information must not be placed in the material's features/characteristics column.

The features column is where the principal points of a drug's efficacy and safety are described. Information placed there is naturally received by the reader as representing the drug's central value. Writing reference information — secondary findings, pharmacological actions of unclear relevance — in that column would misrepresent the evidential tier. The on-page separation is the structural mechanism for preventing that misreading.

The prohibition on placing content in the features column and the requirement to record it explicitly as reference information are two sides of the same rule. The first defines where something must not go; the second defines where and how it may go. Together they inscribe the evidential standing of secondary findings into the layout of the page.

→ Source page: (4) Isolation of reference information

(5) Prohibition of exaggerated or misleading expressions

Pharmaceutical information is subject to two distinct requirements that are alike in appearance but different in reach. The first is not to make false statements. The second is not to mislead. The second sets a higher bar than the first. A text can be free of every factual error yet still leave a reader with a wrong impression, through the selection of evidence, the placement of emphasis, or the cropping of context. What Chapter 1's prohibition on exaggerated and misleading expression targets is precisely that family of techniques — factual statements that nonetheless mislead.

01"Do not lie" and "do not mislead" — the asymmetry of the two requirements

The prohibition on falsehood is a minimum requirement: do not invent numbers, do not claim indications that were not approved. It is the floor that no one may breach. The prohibition on exaggeration asks what lies beyond that floor. An 83% response rate can be perfectly true; if the material does not say which population, which endpoint, and which trial it comes from, a reader will come away thinking "this drug works broadly." No lie is needed to plant that impression.

Understanding this asymmetry changes how the whole of Chapter 1 must be read. Beyond asking "is what is written correct," one must also ask "what will remain in the reader's mind." The same facts, presented differently, leave different impressions. The Guide regulates the manner of presentation, not only its content.

02Emphasizing and guaranteeing safety — the most frequently repeated prohibition

No expression that emphasizes or guarantees the safety of a drug is permitted, and in particular no statement that contradicts the warnings and contraindications in the prescribing information. This prohibition recurs throughout Chapter 1 in various forms. It is the single most frequently stated constraint in the chapter.

"Few adverse reactions" may be true — but few compared to what, which adverse reactions, and over what observation period? The type and frequency of adverse reactions are disclosed in the package insert. Any expression that contradicts that content, or steers the reader away from it, constitutes an exaggeration of safety. Phrases such as "excellent tolerability" or "patients can use it with confidence" carry the same risk. The first question is whether, held against the warnings and contraindications in the package insert, the expression creates a contradiction.

03Authority as impression management — what the photograph prohibition reveals

No false, exaggerated, or potentially misleading expression is permitted with regard to efficacy, safety, or quality. One of the detailed rules under this provision states that materials whose page layout centers on portrait photographs of healthcare professionals must not be made. At first glance this looks like minor guidance on image use. It encodes a more important principle.

When a white-coated physician or prominent specialist occupies the main visual space of a material, a sense of trust in the drug is created before the reader reaches the content. This is a textbook application of authority bias. Nothing exaggerated has been said in words; the look of the page does the work, creating the impression that "authoritative physicians endorse this drug." The detailed rule closes off this technique as a form of misleading expression.

The same logic governs catch phrases, photographs, and illustrations more broadly. Those that could mislead about efficacy or safety, or that damage the dignity of the drug, are not permitted. The regulation of expression is not confined to language. Visual elements fall under the same rules.

04The leap from non-clinical to clinical — crossing the levels of evidence

No expression that directly connects the results of animal or in vitro studies to clinical efficacy or safety is permitted. This prohibition translates the hierarchy of scientific evidence into a rule of expression.

A large proportion of compounds that show an effect in animal models do not produce the expected result in human clinical trials. Mechanism, metabolism, receptor distribution, and immune response all differ across species. In vitro experiments reflect conditions more remote still. Such data can support a hypothesis about mechanism of action; they cannot be directly converted into a claim of clinical efficacy or safety.

When animal or in vitro data are included in a material, the species or condition must always be shown in parentheses — "(rat)," "(in vitro)." That one notation keeps the level of evidence visible to the reader. Narrating non-clinical and clinical data in the same flow, blurring the boundary between them, is the archetypal violation of this prohibition.

05Appeals to emotion — anxiety, fear, and material that damages dignity

Catch phrases, photographs, and illustrations that could mislead about efficacy or safety, or that damage the dignity of the drug, must not be used. Expressions that cause anxiety, fear, or discomfort, and expressions that damage the credibility of pharmaceuticals, are also prohibited.

Anxiety and fear have the power to make a modest benefit look like an urgent solution. Expressions such as "before it's too late" or "without treatment, this cannot be reversed" drive acceptance independent of scientific evidence. This too is a form of exaggeration. Pharmaceutical information is supposed to support considered decision-making. Techniques that manipulate emotion and short-circuit judgment deprive the reader of the chance to evaluate the drug on the evidence.

06Generalizing from exceptional data — the prohibition on cherry-picking

Taking exceptional or limited data and presenting it so as to give the impression that it represents a general fact is prohibited. This is the prohibition on cherry-picking. From the many data points a trial produces, the best result from a subgroup, a time point, or a particular analysis method is selected and placed in the foreground, as though it reflects the overall picture. The numbers are real; the presentation, stripped of context, misleads.

The recurring patterns are recognizable. A subgroup analysis not specified in the original protocol is run on a trial where the overall population showed no significant difference, and only the subgroup result appears in the material. Data that looked favorable at one specific time point are shown in a way that suggests durability. When the primary endpoint showed no difference but a secondary endpoint did, the secondary result is made the lead finding.

Chapter 2's requirements — show only the result of the primary endpoint as the confirmatory analysis item; distinguish exploratory analyses from confirmatory ones — are the concrete implementation of this prohibition. A pre-specified answer to one pre-specified question is confirmatory evidence; a favorable number found after the fact is a reference finding at best. Making that distinction legible to the reader of a material is what the prohibition on generalization requires in practice.

→ Source page: (5) Prohibition of exaggerated or misleading expressions

(6) Prohibition of disparagement

Chapter 1, Section 1(15) of the Guide states: "Do not include descriptions that could lead to disparagement or defamation of other companies or their products." Comparative trial data appear regularly in promotional materials for prescription drugs. Showing a difference from a control drug is a presentation of scientific fact — material that helps healthcare professionals make prescribing decisions. The problem arises when the author's interpretation or evaluation becomes mixed into that data. At that point the material shifts from scientific description toward either a disparagement of a competitor or a self-serving endorsement.

01Report the results; do not evaluate them

Detailed rule (a) states: "When recording the results of a control drug in a comparative clinical trial, do not include an evaluation or commentary on the results." Showing the control drug's numerical results in a material is in principle permitted. What may not be included is any interpretation of those numbers — phrases like "the control drug did not produce an adequate response" or "the investigational drug was significantly superior to the control."

The reason is this: the moment the author annotates the control drug's results, the material retains the appearance of scientific description while functionally becoming a tool for evaluating and criticizing a competitor's product. A numerical result extracted from a particular trial, combined with the author's "commentary," creates an impression in the reader's mind about what that drug is like. That amounts to circulating the author's own assessment of a competitor's product within a promotional material.

Detailed rule (b): emphasizing ineffectiveness, inadequacy, or intolerance

Detailed rule (b) states: "Do not include descriptions that emphasize that treatment with another company's product was ineffective, insufficient, or intolerable in a comparative clinical trial." The number of subjects in the control arm who showed no response, or the number who dropped out due to tolerability problems, may appear in the trial overview as part of the factual record. The issue is emphasis.

• Using bold type or color to highlight only the competitor's figures
• Using phrases such as "many cases were non-responders" or "the drug was not tolerable" in headings or callout boxes
• Using figures or arrows to visually underscore the poor results of the control drug

Such techniques lead the reader from the trial's facts toward the impression that "the control drug cannot be used." Read alongside rule (a) — "do not provide commentary" — the structure of the prohibition becomes clear: even listing numbers can constitute disparagement depending on how they are edited, and rule (b) blocks that. Rule (a) prohibits verbal evaluation; rule (b) prohibits visual and rhetorical manipulation through emphasis.

02Do not provide commentary on prior therapy

Detailed rule (c) states: "Do not provide commentary on prior therapy drugs (products of other companies)." Clinical trials sometimes include patients who switched from one drug to another. Eligibility criteria may specify "patients with an inadequate response to [another company's product]" or "patients who experienced adverse reactions to [another company's product]." These are facts of the trial design.

But going further — explaining what the prior therapy drug is, why it was inadequate, or what its adverse-reaction profile looks like — is not permitted in the material. Doing so embeds content that evaluates a competitor's product within a material that appears to be presenting data for one's own drug. This is precisely the pattern that rules (a) and (b) seek to prevent: an advertising manipulation dressed in the form of factual presentation.

03Other companies' products by generic name; trial facts recorded accurately

Detailed rule (d) states: "In trial overviews, record the names of drugs used (other companies' products by generic name), the dosing period, the dose, the number of cases, and so on as accurately as possible." This rule sets both the scope of permissible information and the manner of recording it.

Why other companies' products are named generically

Other companies' products are referred to by generic name. This is not convention but a deliberate rule. Using a brand name would cause the material to distribute a competitor's trademark. It could also give a strong impression to a particular brand — either disparaging it or inadvertently promoting it. A generic name reduces a drug to its pharmacological identity, a form of reference that carries little evaluative weight. Using scientific vocabulary for competitor products is the technical device that keeps comparative "factual description" from sliding into advertising "evaluation."

When multiple products from the same company appear in a single trial, brand names for own-company products may also be given. The underlying principle is not "own company vs. other company" but rather "does it lead to evaluation or emphasis?"

The duty to record as accurately as possible

The phrase "as accurately as possible" imposes an affirmative obligation: vagueness about dosing period, dose, and case numbers is not permitted. The reason is that if these figures are omitted or imprecise, the reader cannot properly assess the quality of the trial or whether the comparison was made under equivalent conditions.

• Without the dose, it is impossible to judge whether the comparison was conducted on equal terms
• Without the case count, the precision of the effect estimate cannot be evaluated
• Without the dosing period, the interpretation of the observed outcomes may change

Accuracy is demanded so that readers can evaluate the trial on their own. This connects directly to one of the foreword's three pillars: verifiability. Since the author adds no evaluation, the reader must be left with enough accurate information to evaluate independently — that is the function of rule (d).

→ Source page: (6) Prohibition of disparagement

(7) Consistency and updating

A material begins to go out of date the moment it is printed. Drug information keeps moving after approval. When re-examination or re-evaluation results are published, the package insert is rewritten; when post-marketing surveillance identifies a new adverse reaction, a warning is added. Because a Product Information Summary transcribes information as of a particular point in time, that "point in time" is constantly under pressure to be updated.

Items (17) through (20) of Chapter 1, Section 1 address this problem of time directly. Consistency with conditions and instructions at approval, synchronization with the latest official materials, the promptness of revision, and compliance with overarching regulations — these four requirements may look independent, but together they support, from the operational side, the verifiability that the foreword puts forward: keeping the material in a state where its point in time can be traced after the fact.

01Consistency with conditions at approval — fixing the starting point

For new drugs, a substantial body of discussion accumulates during the approval review. The record of deliberations at the Pharmaceutical Affairs and Food Sanitation Council captures both the reasoning behind the evaluation of efficacy and safety and any conditions or instructions that followed from it. A Product Information Summary must be written with "full consideration" of those deliberations.

"Full consideration" sounds abstract, but the substance is concrete. When conditions or instructions were attached at approval — for example, that use in a specific patient group be confirmed first, or that a certain test be performed before starting treatment — the material must be prepared in a way that maintains consistency with the relevant items. Any section of the material that touches on those conditions may not minimize them or render them less visible.

Why return to the time of approval? Approval conditions are the outcome of deliberation that concluded: "This drug requires this brake." Writing without that foundation allows the weight of the information reaching healthcare professionals to diverge from what deliberation actually established. The foreword's "inform accurately without misleading" means accuracy that encompasses conditions and constraints.

02Synchronization with official materials — aligning three windows with the latest version

When preparing or revising a material, consistency must be maintained with the latest package insert, review report, and re-examination and re-evaluation results.

Package insert: the original that keeps being updated

The package insert is the legally authoritative source of drug information, and the latest version is published with each revision. The window that the Product Information Summary holds open looks onto this package insert. In Chapter 2 as well, the Product Information (DI) section is written in accordance with the latest package insert, with its date of preparation or revision noted. Declaring the version lets the reader verify "as of when did this material consult the package insert." Checking alignment starts with comparing versions.

Review report: the published record of the basis for approval

The review report is a public document that shows how the regulatory authority evaluated efficacy and safety during the approval review. It serves as a reference point for confirming that what the material states is not at odds with the facts confirmed during review. The sections that allow narrative — development history, features — are particularly prone to letting claims slip in that diverge from the context of the review.

Re-examination and re-evaluation results: the evaluation that continues to be updated after approval

A drug continues to be evaluated after approval through post-marketing surveillance, use-result surveys, and adverse reaction reporting. When re-examination or re-evaluation results are finalized, they become the latest official evaluation and lead to revisions of the package insert. The requirement to maintain alignment asks that materials follow this continuously moving cycle of evaluation.

03Prompt revision — the danger that time gaps create

When the items that warrant particular attention within indications and dosage, dosage and administration, and precautions including warnings and contraindications are revised, the Product Information Summary must be revised promptly.

Consider what "promptly" means through the lens of information asymmetry. Even after the package insert is revised, as long as the old material continues in circulation, the information in the hands of healthcare professionals diverges from the actual approved content. That time gap is most serious when the revision concerns safety — a new warning added, a contraindication changed, a serious adverse reaction recorded.

Requiring prompt revision for "items that warrant particular attention" clarifies the operational priority. The obligation is not to process every revision at the same speed, but to reflect changes with direct safety implications first. Stated the other way: the requirement makes explicit that revisions to warnings and contraindications rank above minor wording edits in urgency.

04Compliance with overarching regulations — sharing the ceiling of rules

Compliance is required with relevant laws and regulations, including the Act on the Assurance of Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, Regenerative and Cellular Therapy Products, Gene Therapy Products and Cosmetics (the Pharmaceuticals and Medical Devices Act) and the Standards for Fair Advertising, as well as voluntary standards including the JPMA Code and JPMA notifications.

The two-tier structure of law and voluntary norms

The PMD Act and the Standards for Fair Advertising draw the legal ceiling. Below them, the JPMA Code and JPMA notifications are the behavioral norms the industry has set for itself. The Preparation Guide operates as the individual implementation rules below both tiers. It follows that even where the Guide is silent, the law and voluntary norms provide the direction for a judgment.

05Connection to the foreword's three pillars

The alignment and updating group implements the foreword's three pillars — verifiability, accuracy, and transparency — along the dimension of time.

The nature of a material — that it begins to go out of date the moment it is printed — cannot be changed. That is precisely why declaring the version, synchronizing with official materials, following safety revisions without delay, and remaining within the regulatory framework matter. By holding to these four points, a material that is only a snapshot of one moment can maintain its trustworthiness as a verifiable record.

→ Source page: (7) Consistency and updating

(8) Data reliability and accuracy

Data reliability and accuracy form the first gate controlling what data may appear in promotional materials for prescription drugs. No matter how favorable a number looks, one question determines whether it may be used: was it the answer to a question decided before the data were collected? The fact that a result has been published, or has passed peer review, is a necessary condition for reliability — but it is not sufficient.

01Confirmatory vs. exploratory analysis — why the distinction is the condition of inclusion

Clinical trials normally define a statistical analysis plan (SAP) before the study begins: the primary endpoint, secondary endpoints, how multiplicity will be adjusted, and any subgroups considered in advance. This is pre-specification — locking in "what are we testing" before any data are seen.

Without pre-specification, statistics can prove almost anything. Slice the population into twenty subgroups and one will likely cross the 5% threshold by chance alone. Exploratory analysis is the place where hypotheses are generated, not the place where they are confirmed. The Guide encodes this principle as a rule: results may not be recorded unless they come from pre-specified analyses with scientific validity.

Where subgroup analyses stand

A subgroup analysis may be included only if the statistical method for that subgroup was set out in the analysis plan before the study ended. A finding that emerged from dividing patients after the data were collected — "we split the group this way and got significance" — is a post-hoc exploration. It cannot serve as confirmatory evidence. If it is to appear at all, it must follow the rules for post-hoc analyses described below.

02Post-hoc analyses — the conditions for inclusion and required disclosures

Post-hoc analyses are not banned outright. Where the informational value is high — a result suggesting important risk factors for a serious adverse reaction, or data used as the efficacy basis for an orphan drug where few patients make a conventional powered trial impractical — inclusion may be warranted. But conditions apply.

What this requirement secures is that the reader can tell, on the page itself, whether a result confirmed a hypothesis or searched for one. Placing post-hoc results beside confirmatory results without distinction would give the reader a false sense of certainty — the foreword's duty to "close off misunderstanding" applies directly here.

03Meta-analyses — what it means to be a systematic review

A meta-analysis pools multiple trials statistically, which can appear to provide greater power than any single study. But the quality of the pooling depends entirely on how systematically the literature was collected and selected. Selectively gathering favorable studies makes a meta-analysis a device for amplifying bias rather than reducing it.

The Guide is explicit: a meta-analysis may be included only if it is based on a systematic review. The following information must also be recorded.

• Search sources (names of databases used)
• Search keywords
• Total number of records identified
• Total number of articles assessed for eligibility
• Number of articles excluded and the reasons for exclusion

Why is this level of detail required? So that the reader — or a later auditor — can trace "where was searched, what was selected, and what was dropped." A meta-analysis that does not disclose its search process offers no way to verify whether studies were excluded by design. This extends the foreword's principle of verifiability all the way into the mechanics of evidence synthesis.

04The trap of "published means pre-planned"

A clinical trial conducted for a regulatory submission may later be written up and published in a journal. The fact that a paper passed peer review raises the apparent standing of the analysis. Yet if the publication involved a re-analysis that departed from the original statistical analysis plan, that published result is treated as post-hoc.

This is an easy blind spot in practice. The reasoning "it is a peer-reviewed original article, so it qualifies" seems sound. But peer review evaluates the internal logic of a paper and the quality of its reporting — it does not verify alignment with the pre-submission analysis plan. A clinical trial conducted for a regulatory application that is later re-analyzed when written up is treated as a post-hoc analysis regardless of publication, and may not be used as confirmatory evidence.

05Accuracy: three prohibitions — distortion, cherry-picking, and cropping

If reliability is a question of which data may be used, accuracy is a question of how the data that are used must be shown. The Guide forbids three things.

① Do not intentionally distort the source information

The figures, directions, and context that the trial results show must not be reshaped inside the material. Emphasizing only the relative risk reduction while obscuring a small absolute risk reduction, or making confidence intervals hard to see — these "visual operations" are forms of distortion.

② Do not conduct multiple analyses and present only the results convenient for interpretation

When multiple analyses are run, selecting only the favorable results for presentation is prohibited. This is cherry-picking. A structure that foregrounds a significant subgroup finding while a primary endpoint failed to reach its threshold is a direct violation of this rule.

③ Do not extract convenient portions from figures or tables in original articles

When transferring figures or tables from a publication into a material, it is not permitted to omit the overall trend or the control arm results in order to show only the portion favorable to the drug. Cutting the y-axis away from zero, or showing only a selected segment of a time series, is structurally the same offense.

→ Source page: (8) Data reliability and accuracy

(9) Statistical and graphical conventions

Statistics are colorless on their own. The same number, depending on how it is presented, can read as "a scientifically confirmed effect" or as "an exploratory reference value." The provisions on statistics and figures in Section 2 of Chapter 1 exist to close that gap. More than which numbers to report, the requirement is to state clearly in what context each number appears and what it can and cannot show — that is how the foreword's three pillars, "treat the package insert as the original, inform accurately without misleading, and keep the record verifiable," take concrete form at the point of statistical reporting.

01Reporting statistical results — what to write and how far to go

When statistical analysis results are included in a material, the analytical method and its results — confidence intervals (= the range within which the estimate is likely to fall) and p-values (= a rough measure of how often a difference this large would arise by chance) — must be stated. The conventional assumption is a two-sided 5% significance level (= the probability cutoff for judging a result "not due to chance"); any deviation from this must be explicitly noted. A bare statement of "statistically significant" leaves the reader no way to check the claim. Writing the method and the level is what makes the result verifiable.

Detailed rule a: when the analysis is adjusted, name the adjusting variables in the results

When covariates — baseline characteristics, prognostic factors, and so on — or stratification factors (= the way subjects are divided into layers, such as by age or severity, for comparison) are used to adjust the analysis, the variables used must be named in the results section. This applies to multivariate regression (= a method that compares groups while subtracting the effects of several factors at once), to stratified Wilcoxon or log-rank tests (= comparing survival or time-to-event separately within each layer), and to all comparable approaches. Without the adjustment variables, the reader cannot tell a crude comparison (= a raw, unadjusted comparison) from an adjusted estimate. When both types sit in the same table, distinguishing them is the writer's responsibility.

Detailed rule b: a statistical model without a standard name requires its equation

If the statistical model used does not carry a commonly recognized name, its equation (= the calculation steps written out as a formula) must be stated in the results. An established name such as "Bayesian hierarchical model" (= a method that estimates probabilistically across layers of data) or "modified Poisson regression" (= a regression that estimates proportions or risk ratios) can be supplemented with a reference. A bespoke model or a non-standard extension, by contrast, is impossible to reproduce or verify from a name alone. Providing the equation is the minimum condition for verifiability.

Detailed rule c: when missing values are imputed, state the imputation method

If missing values (= data that could not be measured or was left unrecorded) are imputed — that is, filled in — before aggregation or analysis, the imputation method must be stated. The estimates shift depending on the method: single imputation (= filling a gap with one value), multiple imputation (= filling gaps with several candidate values so the resulting uncertainty is also captured), last observation carried forward (LOCF = continuing to use the last measured value thereafter), or a mixed-effects model for repeated measures (MMRM = a statistical model that handles all the repeated measurements together). Imputed data without a stated method cannot be distinguished from directly observed data. Making clear where observation ends and estimation begins is what accurate communication requires.

02What statistics can and cannot say

A p-value is only "the probability that, assuming the null hypothesis (= the provisional premise that 'there is no difference') is true, a difference at least as large as observed would arise by chance." It does not directly speak to the size of the effect, clinical importance, or reproducibility. A confidence interval conveys the precision of an estimate but does not by itself guarantee causation (= an actual cause-and-effect relationship). And a nominal p-value — any p-value from analyses other than the pre-specified confirmatory analysis — is liable to arise from the repeated testing of multiple analyses and cannot serve as the basis for a confirmatory conclusion.

When no statistically significant difference was found, or when no statistical analysis was performed, the result is limited to presenting the numerical values alone. A non-significant result may hide a large absolute difference or may reflect a negligible gap that is clinically irrelevant. Placing the numbers and leaving the judgment to the reader is the boundary the writer must not cross.

03Subgroup analyses — representing their exploratory nature honestly

Most subgroup analyses (= analyses limited to a portion of patients, for example by age or disease type) remain exploratory (= at the "looking for clues" stage rather than a conclusion). This is a statistical reality. Applying the significance level set for the primary analysis to each of several subgroups accumulates the probability of a chance significant finding with each additional comparison — the problem of multiplicity (= repeating many tests inflates the chance of an accidental "hit"). A subgroup analysis that was not pre-planned easily becomes a tool for highlighting a favorable number while carrying the appearance of a significance test.

Hence the conditions the Guide sets. Subgroup analyses may be included only if they were specified in the original trial plan and are scientifically valid. Where the full-population analysis has also been conducted, the subgroup results must be presented alongside those for the full population. Selecting a subgroup result and placing it in the foreground — even where that subset showed favorable numbers — is not permitted.

04Graphs and tables — keeping visual presentation from overwriting the numbers

Graphs and tables compress data into an impression, but they also add impressions the numbers themselves do not carry. Moving the y-axis baseline away from zero makes a small difference look large. An arrow draws the eye to the gap. Heavier weight or stronger color on one bar causes the reader to set the other aside before forming a judgment. The Guide devotes substantial attention to the detailed rules for figures precisely because visual misleading is harder to detect than a numerical transcription error.

Name which numerical quantity is being shown

Whether the figure shows a mean, a median (= the middle value when the data are ordered by size), a geometric mean (= an average obtained by multiplying values, suited to ratio data), or a least-squares estimate (= a value adjusted for background factors) must always be stated explicitly. Means and medians diverge in skewed distributions; least-squares estimates are adjusted values. Whether the legend reads "Mean ± SD" (= mean ± standard deviation, the width of variation) or "Median (IQR)" (= median and interquartile range, the spread of the middle 50% of the data) changes the meaning of an otherwise identical bar chart. If the presence or absence of a statistically significant difference is shown, the statistical method used must be named.

Five prohibitions — visual operations that inflate differences

(1) Do not merge data from conditions that are not comparable into the same graph or table. Placing results from trials with different doses or different target populations on a single graph creates the appearance of comparison where there is none. (2) Do not manipulate the scale of the axes beyond what is necessary to exaggerate a difference. (3) Do not use arrows or similar devices to visually emphasize the gap in comparisons between the drug and a control drug (including placebo), or in before-and-after administration comparisons. (4) Do not use text size or color to draw attention to one set of numbers over another. (5) Do not add adjectives that describe the size of the difference without a quantitative basis — words like "markedly," "substantially," or "clearly" are additions the numbers themselves do not justify.

05Citing original papers — where selective excerption distorts intent

When data are cited from an original paper, the material must be recorded so the content is accurately conveyed, must not excerpt only the portion of the conclusion that is favorable to the company's product, must not distort the true intent of the original paper, and must clearly state the source. This single sentence blocks a layered set of common failures.

The first layer is "accurately conveyed." Cutting out only one figure without its context, or presenting follow-up periods and primary endpoints (= the evaluation measure fixed in advance as the most important) from one trial in a way that suggests they belong to another, violates this requirement. The second layer is "not excerpt only the favorable portion." If the same paper contains an unfavorable subgroup result or a discordant secondary endpoint (= a secondary measure that supplements the primary endpoint), those cannot be withheld while the favorable numbers are shown. The third layer is "not distort the true intent." Citing a trial whose authors concluded "this finding remains exploratory" as evidence of a confirmed effect is falsification of intent.

Stating the source is part of verifiability. A full bibliographic reference — title, journal, year, volume, and pages — lets the reader return to the original and check the whole. A citation presents a part while implying the part represents the whole, and without the reference to let that claim be checked, the implied endorsement is borrowed rather than earned.

→ Source page: (9) Statistical and graphical conventions

Glossary — defining key terms from Chapter 1

For each provision of Chapter 1 of the Creation Guide to function precisely, the words it uses must carry the same meaning for everyone reading them. The distinction between confirmatory and exploratory analysis, the scope of what "pre-specification" covers, the difference between a non-proprietary name and a brand name — when the same term is read with different meanings, even the most carefully worded rule will be applied inconsistently in practice.

01Why precise definitions are necessary

The language used to govern promotional materials for prescription drugs is a mixture of words borrowed from everyday use and words carrying specialized meanings in scientific or regulatory contexts. "Efficacy" is used as an ordinary word, yet in the context of a clinical trial it takes the restricted meaning of "effect shown on a pre-specified primary endpoint." The prohibition on "emphasizing safety" does not forbid discussing safety at all — it forbids assurance-type language that goes beyond what the evidence supports.

When the underlying meanings of such terms are not shared, people reading the same provision will reach different conclusions about where the boundary lies. The Glossary exists to prevent that variation through structure.

Common patterns where confusion generates misreading

Certain pairs of terms tend to generate confusion in practice. In scientific and statistical language, "confirmatory" and "exploratory" are commonly conflated, and the nominal p-value is repeatedly misused as though it carries the same weight as a confirmatory result. In regulatory language, "approved indication" and "clinical positioning" are sometimes confused, creating the risk that off-label claims are presented as approved information. In the language of expression controls, "emphasis," "assurance," and "misleading" are used loosely, blurring the edges of the provisions that depend on them.

02The three categories of the Glossary

The pages under this chapter organize terms into three categories according to their nature.

Scientific and statistical terms

This category covers the statistical and clinical-trial methodology vocabulary that Chapter 1's provisions rely on. It includes the distinction between confirmatory and exploratory analysis, the requirements for pre-specification, the standing of subgroup analyses, the relationship between meta-analysis and systematic review, and the interpretation of p-values and confidence intervals. When these terms are left undefined, judgments about which data may appear in a material will vary from person to person.

Approval and regulatory terms

This category covers terms that carry specific meanings in the pharmaceutical regulatory context. It includes approved indication, dosage and administration, qualifier language (shibari hyōgen), the electronic package insert, data evaluated during regulatory review, and post-marketing re-examination materials. These words belong to the official record that the Creation Guide references, and they must be understood as distinct from their everyday usage.

Expression-control terms

This category covers the vocabulary used to identify the types of expression the Creation Guide prohibits. It includes false or exaggerated claims, expressions likely to cause misunderstanding, emphasis of efficacy or safety, comparative advertising, and reference information. Understanding the difference between "emphasis" and "clear statement," and the scope of "likely to cause misunderstanding," is essential to applying the provisions accurately.

→ Source page: Glossary — defining key terms from Chapter 1

Scientific and statistical terms

Statistics are a compressed language for facts. The same number carries a different evidentiary weight depending on whether it came from "a pre-specified analysis confirming a single pre-fixed hypothesis" or from "a promising trend discovered after seeing the results." When the definitions of terms are not held precisely, the same words can be used to smuggle in claims of very different strength. This section defines each scientific and statistical term that appears in Chapter 1 — in the order of definition, what it means, and where misreading tends to occur.

01Confirmatory and exploratory analysis — the classification is decided before the trial begins

A confirmatory analysis is one in which a single hypothesis is fixed before the trial starts, and the analysis is designed specifically to test that hypothesis. The hypothesis, the primary endpoint, the testing method, and the significance level are all recorded in the protocol before a single patient is enrolled. The p-value that results from this analysis can be compared to the pre-set significance level to determine whether the null hypothesis is rejected or retained. This is the only category of analysis whose results can serve as grounds for a statistical conclusion.

An exploratory analysis is conducted to generate hypotheses. It is performed either without a prior hypothesis or to answer a question that was not planned in the protocol. It can identify promising directions for future research, but that is its function — pointing toward what should be confirmed in a subsequent trial. No matter how small the p-value, an exploratory result is not confirmation. Confirmation requires a new independent trial in which that hypothesis is designated as the primary pre-specified hypothesis.

02The p-value — what it asserts and what it does not

The definition of a p-value is one thing: "the probability that, assuming the null hypothesis is true, a difference at least as large as observed would arise by chance." No claim that falls outside this definition is warranted by the p-value.

Three things a p-value cannot speak to. First, the size of the effect. p = 0.001 does not mean a larger difference than p = 0.04. With a large sample, a clinically negligible difference can produce p = 0.001. Second, clinical relevance. Whether a statistically significant difference matters to patients is a separate question. Third, causation. A p-value from an observational study cannot control for confounders. The reading "p < 0.05 therefore there is an effect" exceeds what the definition supports.

A 95% confidence interval supplements the p-value by conveying a "range" the p-value does not provide. Rather than a point estimate alone, it shows the spread of uncertainty around the estimate. It is not, however, a guarantee of causation, nor a statement of the probability that the true value falls within the interval. The width of the interval reflects the precision of the estimate — wider when data are sparse, narrower when data are abundant.

03Nominal p-value — the definition, word for word

The definition of a nominal p-value is: any p-value obtained from analyses other than the pre-specified confirmatory analysis.

The critical phrase is "other than the pre-specified confirmatory analysis." This is not a question of the type of analysis or the statistical method used. It is a question of where the analysis stands in the trial plan. Secondary endpoint analyses, post-hoc subgroup analyses, sensitivity analyses, exploratory biomarker analyses — all of these lie outside the pre-specified primary confirmatory analysis. Every p-value obtained from them is a nominal p-value.

The reason a nominal p-value cannot support a confirmatory conclusion is multiplicity. When multiple analyses are repeated, the probability that at least one produces a chance significant result accumulates with the number of tests. Without having fixed a single hypothesis in advance as the confirmatory test, a result of "this analysis was significant" cannot be distinguished from a chance finding.

Including a nominal p-value in a promotional material is not prohibited. It may be presented as reference information for hypothesis generation. What it cannot do is serve as grounds for a confirmatory conclusion, support a declaration of "statistically significant difference," or confirm superiority or non-inferiority. When a p-value is reported, the context must make clear which category of p-value it is.

04Hazard ratio — a ratio of relative rates, not an absolute reduction

A hazard ratio is the ratio of the rate of event occurrence between two groups at any given point in time. A hazard ratio of 0.7 means the event rate in the treatment group is 0.7 times that in the control group at any given moment. It is widely used in survival analyses and is typically estimated from a Cox proportional hazards model.

Two misreadings to avoid. The first is the translation "risk reduced by 30%." A hazard ratio of 0.7 is a relative ratio, not an absolute risk difference. The absolute risk difference requires a separate calculation. The second is describing a direction of effect when no significant difference was found. When no statistically significant difference exists, using the numerical value of the hazard ratio to assert a "trend toward risk reduction" or "30% improvement" is not permitted. The result is limited to presenting the value, without evaluative language.

05Meta-analysis and systematic review — transparency as a requirement

A systematic review collects and evaluates studies relevant to a defined question according to a pre-specified search strategy and eligibility criteria. A meta-analysis statistically pools the results from the collected studies to produce an overall estimate, and is often conducted as part of a systematic review.

When citing these in promotional materials, certain elements must be stated. Which databases were searched (search sources), what search terms and combinations were used (search strategy), and on what criteria studies were included or excluded (eligibility criteria with the reasoning) — without all three, the claim that the collection was "systematic" cannot be verified. The transparency of the search is the minimum condition for the reader to assess selection bias.

06Post-hoc analysis and subgroup analysis — declaring the exploratory character explicitly

Post-hoc analysis refers broadly to analyses that were planned and conducted after seeing the trial results. Knowing the outcome before designing the test creates room for conscious or unconscious selection — choosing the analysis that shows the most favorable result. This is the fundamental reason why post-hoc analyses cannot be used for confirmation: the structure has become "form a hypothesis from the results" rather than "fix a hypothesis, then confirm it."

A subgroup analysis restricts the analysis to a subset of the full population. Most remain exploratory. Applying the significance level from the primary analysis to each of several subgroups causes the probability of a chance significant finding to accumulate with each additional comparison. Subgroup analyses may be included in materials only if they were pre-specified in the original trial plan and are scientifically valid. Where the full-population analysis was also conducted, the subgroup results must be presented alongside the full-population results. Selecting a favorable subgroup result and placing it in the foreground — even where the subset showed good numbers — is not permitted.

07Types of summary statistic — a single word in the legend changes the meaning

Even under the umbrella of "average," different summary statistics produce different numbers and carry different assumptions.

The mean is the sum of all values divided by the number of observations. It is sensitive to outliers and can diverge from the typical value when the distribution is skewed. The median is the middle value when data are arranged in order. It is resistant to outliers and, in skewed distributions, often a better representation of the typical value than the mean. The geometric mean is computed by taking the arithmetic mean on the log scale and back-transforming. It is appropriate for data that follow a log-normal distribution, such as pharmacokinetic parameters like AUC and C_max. The least-squares mean (LS mean) is a model-based estimate after adjustment for covariates. It is an adjusted figure, not a crude observation, and this must be stated clearly — otherwise it is indistinguishable from directly observed data.

Without stating the type of statistic in the figure legend, the reader has no way to tell which is which. Whether the legend reads "Mean ± SD" or "Median (IQR)" changes the interpretation of an otherwise identical bar chart. When reporting the presence or absence of a statistically significant difference, the statistical method used must also be named.

08Two-sided 5% significance level — the default, not the only permissible value

The significance level α = 0.05 (two-sided 5%) is the conventional default widely adopted in pharmaceutical clinical trials. It sets at 5% the probability of observing a result this extreme when the null hypothesis is true. A two-sided test assumes that the treatment group could differ from the control in either direction, and is the standard approach where the possibility of a difference in either direction is not ruled out a priori.

This is a default, not the only permissible setting. Extension trials, safety evaluations, dose-finding studies, and other designs may use a different significance level for clearly stated scientific reasons. In those cases, the significance level actually used must be stated in the material. A bare statement of "statistically significant" without a stated significance level gives the reader no way to check the claim. Stating the level used is the minimum condition for a verifiable record.

→ Source page: Scientific and statistical terms

Approval and regulatory terms

Before writing any section of a product information summary, the author must know the precise contour of the approval. The electronic package insert, the approved indications, and the approved dosage are the reference lines against which every line in the material is measured. Beyond these fixed points, post-approval evidence — RMP, early post-marketing phase vigilance, re-examination and re-evaluation, and real-world evidence — does not widen the approval; it reinforces the evidentiary foundation that the approval rests on across time. Peer-reviewed original articles underwrite the quality of that foundation.

01Term reference — regulatory and approval vocabulary

02The electronic package insert — what it means to be the primary source

The product information summary supplements the package insert; it does not precede it. The starting point for every line in any material is the package insert, and nothing may be stated in a material that the package insert does not contain.

The corollary is equally important. The risk information the package insert communicates — warnings, contraindications, serious adverse reactions — exists as a prior fact that no material can ignore. When a material selects only the safety information that favors the product, a substantive discrepancy with the package insert emerges. Recognizing the package insert as the primary source is the foundation of what the foreword calls the "asymmetric obligation" — the duty to disclose information even when it is unfavorable to the company.

03Qualifying wording — reproducing the approval means copying the condition too

Qualifying (restrictive) wording is a limiting condition attached to an indication. "Only when [treatment X] is inappropriate," "patients for whom existing therapies have proved insufficient" — these phrases are not contextual color added to the indication; they are part of the definition of the indication itself.

Dropping the condition alters the approval

What happens when an indication is written in a product information summary without its qualifying wording? The healthcare professional reading it understands that the indication may be used without restriction. What the package insert approved conditionally appears in the material as an unconditional approval. This is not a reproduction of the approved fact; it is an alteration of it.

The same standard applies in every column where the indication is mentioned — the development history column, the features column, and anywhere else. When domestic and overseas indications differ, the domestic approved content must be written separately and include the qualifying wording in full.

04Reference information — the partition from the features column must hold

Reference information consists of findings obtained incidentally within an approved study — QoL measurements, biomarker changes, exploratory subgroup analyses. These are not the confirmatory results of the primary endpoint, which is what the features column is reserved for.

Reference information must be clearly labeled as such. The features column must contain only confirmatory primary results; placing reference information there is impermissible. The features column is the section most prone to exaggeration, and when secondary findings infiltrate it, unconfirmed knowledge begins to carry the same apparent weight as the evidentiary basis for the approval. The foreword pillar of "blocking misunderstanding" is put into practice precisely by maintaining this partition.

05RWE and peer-reviewed articles — evidence quality and verifiability

Real-world evidence (RWE) is knowledge drawn from routine clinical data. Because it is not a randomized controlled trial, it inherently carries risks of selection bias, confounding, and inconsistent observation periods. Placing RWE on equal footing with RCT results is not permitted. When RWE is included in a material, the text must state that it is derived from real-world data and identify the design's limitations.

A peer-reviewed original article — whether it reports an RCT or a real-world study — is the most verifiable form of citation available. When citing, author, journal, volume, issue, and year must be given so that the reader can trace back to the primary source. This is the concrete implementation of the foreword's third pillar: verifiability. Press releases and conference slides are not acceptable substitutes.

→ Source page: Approval and regulatory terms

Expression-related regulatory terms

The expression standards that pharmaceutical materials must meet sit one level above the prohibition on stating falsehoods. A text composed entirely of facts can still leave the reader with a false impression — through the selection of which facts to include, where emphasis is placed, what is omitted, and how the page is laid out. This is why the decisions a writer makes are judged not only by "is what I wrote accurate?" but by "what will the reader take away?" The terms defined in this category are the vocabulary needed to answer that second question.

01Term reference — expression regulation vocabulary

02Exaggerated expression — the requirement goes one step beyond prohibiting falsehood

What separates the prohibition on exaggeration from the prohibition on falsehood is the object of scrutiny. The prohibition on falsehood asks whether what was stated is true. The prohibition on exaggeration asks whether the impression the reader forms is warranted. An efficacy rate of 83% can be an accurate number and still create an exaggerated impression if the material conceals which population it came from, which endpoint it measured, and how the study was designed. No falsehood is needed to plant a misleading belief.

Four recurring types

Exaggerated expressions recur in recognizable patterns: ① emphasis on or guarantee of safety (claims that conflict with the package insert's warnings), ② authority-based impression management (materials centered on portraits of healthcare professionals), ③ bridging non-clinical evidence to clinical claims (connecting animal or in vitro results to clinical efficacy), and ④ generalizing from exceptional data (presenting unplanned subgroup analyses or secondary endpoint results as if they described the full trial population). None of these requires a stated falsehood; all of them exploit the gap between what was said and what the reader concludes.

03Disparagement — the line between factual comparison and evaluative commentary

A comparison with a competitor's product may be made by presenting facts from an appropriately designed trial. Stating that "in trial A, the company's product showed an improvement of X on the primary endpoint" is permissible. Stating that "the competitor's product has unacceptable tolerability" or "patients who failed on the other agent responded to this one" is evaluative commentary and constitutes disparagement.

The distinction matters because disparaging a competitor and exaggerating a company's own product frequently arise from the same passage. Placing a competitor in an unfavorable light produces the same effect as stating that the company's product is superior to what the evidence warrants. Eliminating evaluative commentary about competitors is part of what the foreword pillar of "blocking misunderstanding" requires.

04Asymmetric obligation — disclosing unfavorable information is not optional

The obligation on the material's author is to apply the same disclosure standard to favorable and unfavorable information alike. Safety information that reflects unfavorably on the company — adverse reaction frequencies, the content of warnings, precautions relevant to specific patient populations — must be disclosed.

But disclosure is not satisfied by mere inclusion. If unfavorable information appears in small type at the bottom of the page, or in an electronic material behind a click that the reader may never perform, it has not been effectively disclosed. The page-level implementation of balance is the design requirement that ensures effective disclosure — the same obligation expressed in the language of page architecture.

Relationship to the prohibition on safety emphasis and guarantees

The requirement to disclose unfavorable information and the prohibition on emphasizing or guaranteeing safety are two sides of the same principle. An author who is obligated to disclose a warning on the same page where a safety guarantee is printed places the reader in the position of receiving contradictory information. The Guide's repeated prohibition on safety emphasis and guarantees reflects the fact that this contradiction arises most often in this exact context.

05Balance (page-level implementation) — equal visibility for efficacy and safety

Balance is not a conceptual aspiration; it is a design obligation. When efficacy information appears in a product information summary, safety information — the outline of warnings, precautions, and adverse reactions — must be presented at equal or greater type size.

The practical implication is precise. When an efficacy graph and a safety table appear on the same page, if the graph is large and the table is reduced to supplementary fine print, the reader's attention will concentrate on efficacy. Even without any intent to minimize safety, the cognitive result is that safety recedes. The page-level implementation of balance is a design-stage correction for this unintentional bias.

06The features column — where exaggeration is most tempting

The features column exists to communicate the product's primary characteristics concisely. It is also the section of any material where the pressure toward exaggeration is strongest. The word "features" carries the connotation of "what sets this apart" and "what is superior" — an invitation to select and amplify.

Only confirmatory primary results, grounded in the approved evidence, may appear in the features column. Reference information stays out. So do subgroup-limited results, results from indications not approved domestically, and exploratory analyses. The more compelling a result seems as a "feature," the more likely it is that the underlying data do not come from a confirmatory primary endpoint. A clear prohibition is necessary to resist that pressure, and the Guide places it here.

→ Source page: Expression-related regulatory terms

Chapter 2: Comprehensive Product Information Summary

Chapter 2 covers the Comprehensive Product Information Summary, the main body of Part I. It gathers the full picture of a single prescription drug — efficacy, safety, and handling — into one document so that healthcare professionals can take in, at a glance, everything they need for a prescribing decision. It is the thickest and most rigidly structured material of all. Where Chapter 1 set out ground rules that apply to any material, this chapter has one defining feature: the Guide dictates what must be included, and in what order.

01Why the fixed items and order are a design philosophy

There are two forms. The Comprehensive Product Information Summary covers the whole picture; the Specific-Item Product Information Summary narrows to selected items. Even the latter cannot escape Chapter 1's basic considerations, and for the items it does cover it must follow the relevant Chapter 2 rules. In other words, "keeping it short" is allowed; "diluting the rules" is not.

Sixteen items are prescribed: (1) items on the cover, (2) development history, (3) features/characteristics, (4) product information (DI), (5) clinical results, (6) pharmacokinetics, (7) pharmacology, (8) safety pharmacology and toxicity studies, (9) physicochemical properties of the active ingredient, (10) pharmaceutical matters, (11) handling precautions, (12) packaging, (13) related information, (14) principal references, (15) the name and address of the marketing authorization holder, and (16) the date of preparation or revision.

What the sequence itself says

These sixteen items are not a loose bullet list. Read in order, they form a single arc. Development history explains why the drug came to be; features and clinical results present the core of efficacy; pharmacokinetics, pharmacology, and toxicity establish the drug's profile; handling and packaging carry the practical detail; and the document always closes with principal references (where the evidence lives) and the date of preparation or revision (which version this is).

That the ending is sealed with "references" and "date" is no accident. State a claim, then always end by attaching its source and its point in time — this implements, at the level of the table of contents, the foreword's idea of guaranteeing verifiability through structure. By looking at the final two items, a reader can always return to the primary source and check whether the version is current.

02The cover — placing the most critical safety information in first sight

Item (1), the cover, is the product's "face," one of the few places where the Guide reaches into how things look. It carries the Japanese Standard Commodity Classification number (down to the detailed subclass), the therapeutic classification name consistent with the product title, the regulatory category, the name, and whether the drug is listed in the NHI price standard. For the regulatory category, the full text of the applicable designation — poisonous/powerful drug, narcotic, psychotropic, prescription-only drug, conditional approval, and so on — is appended to the name.

A new drug subject to post-marketing surveillance carries the unified mark on the cover for six months after launch. A product with a Risk Management Plan (RMP) is marked "Risk Management Plan target product" on the cover. Specifying point size, typeface, and framing may look excessive. But if "inform accurately without misleading" is taken seriously, then the size and placement of text are exactly what determine the quality of communication. Safety information that is small and tucked into a corner has merely been "included," not "communicated."

03Development history and features — brakes that keep the story from running away

(2) Development history: tell the story, but never depart from the approved facts

You may describe the background to development, the development process, the clinical positioning, and the overseas approval and marketing status. It is one of the few columns where a narrative is allowed — which is precisely why brakes are fitted. When efficacy, indications, or dosage differ between overseas and Japan, the domestic approval content must be written out accurately, including any restrictive wording. References to existing drugs must not become disparagement of competitors. If improved safety was the main aim of development, that may be stated, but it must not turn into emphasis or a guarantee of safety.

(3) Features/characteristics: the column most prone to exaggeration

The features column is where the writer most wants to "sell," and therefore the one most prone to exaggeration. The Guide lays a dense set of constraints here. Write efficacy and safety in balance; make no false or exaggerated claims of efficacy and no emphasis or guarantee of safety. Do not contradict the warnings and contraindications. State indications and dosage accurately, restrictive wording included. Do not put "reference information" in this column. If you state efficacy or safety, carry the supporting data within the material and cite the page where it appears.

Detailed rule: brakes that reach even how figures are drawn

Figures in the features column carry a concrete fifth-level rule. If the number of cases is fewer than ten, do not graph the response rate or express it as a percentage; show it as raw counts ("● of ■ cases"). Turning a handful of cases into a percentage makes the result look more certain than it is. When there is no significant difference, the hazard ratio may be shown, but the relative risk reduction must not be written. Differences from a control must not be visually emphasized with arrows and the like. Safety must be consistent with the package insert; note the serious adverse reactions, the major adverse reactions, and the fact that the package insert and the clinical-results safety findings are to be consulted. The adverse reactions of placebo or the control drug are not written in this column. Animal data are labeled "(animal species)" and in vitro data "(in vitro)," and are not connected directly to the clinic.

04Product information (DI) — keeping the window onto approved facts in sync with the latest version

Item (4), product information (drug information), is the "window" onto approved facts placed inside the material. At the top of the relevant page, state prominently that one must pay close attention to revisions of the precautions and related information, including warnings and contraindications; write in accordance with the latest package insert; and note that package insert's date of preparation or revision. A material can begin to go out of date the moment it is printed. So it declares of its own accord, "as of when did I transcribe the approved information." This too is part of verifiability.

05Clinical results — the thickest chapter in the Guide

Item (5), clinical results, presents the core of efficacy and is the most voluminous item in the Guide. Yet the gateway for "data that may be carried" is tightly narrowed.

The range of trial results that may be carried

• Results evaluated during the domestic approval review
• Evaluation materials used at the time of package insert revision
• Original papers that have undergone rigorous peer review (conference presentation data and review articles excluded)
• Results evaluated as re-examination application materials

Note that peer review is the watershed of quality. In the evidence hierarchy, meta-analyses, systematic reviews, and RCTs sit at the top, while non-peer-reviewed conference presentations and reviews are hard to use as evidence as they stand. A comparative clinical trial may be carried only if it is double-blind, randomized, or material evaluated during the approval review as an accepted substitute for a double-blind design. Randomization evens out known and unknown biases; blinding removes the bias of expectation and subjectivity. The quality of the design is itself the condition for inclusion.

The four conditions for RWE (real-world evidence)

To carry real-world data, four conditions must be met: it reinforces or supplements the approved scope; the fairness of control, concomitant, and reference drugs is secured; it is presented alongside the confirmatory trial (usually an RCT) that is the principal basis of approval; and the important limitations from bias are stated prominently. RWE reflects real practice but is prone to confounding. Hence the stance required: do not let it stand alone as the lead, and do not hide its limits.

Items to record and the "explicit positioning"

Clinical results record the trial title (phase; the control drug by generic name; own-company drugs may be shown by brand name), the type of trial (note overseas data or international joint trials), the trial method (objective, subjects, number of cases, dosing, endpoints, analysis plan, judgment criteria), the source, and conflicts of interest. Most important is distinguishing the positioning of endpoints: make clear which is a confirmatory analysis item and which is no more than a nominal p-value.

Detailed rule: safety is handled differently depending on the column

For the very same drug, how safety is handled changes with the column it is written in. This is an easy place to err.

The principle of not emphasizing safety runs throughout. One does not wheel out a significance test showing no difference from placebo to create the impression that the drug "is safe." Control-drug results may be carried as fact, but not evaluated or commented on. This is the asymmetric duty the foreword describes — safety-related information is disclosed even when it is unfavorable to one's own company.

Detailed rule: a presentation that never steps beyond the approved scope

As a rule, present within the approved scope. Even where dose adjustment is permitted, do not carry efficacy data above the approved dose. Do not use trial data inconsistent with the starting dose or the method of adjustment. A dose-finding trial that includes off-label dose groups must be labeled "dose-finding trial," with the approved dosage noted. When presenting results that include off-label content, state at the outset "the fact that part is off-label and the reason for inclusion," and note the corresponding indication and dosage. Results in which a dose group contains off-label cases may not be conveniently re-analyzed. Subgroup analyses are not carried, except those that were in the original plan and are scientifically valid.

Detailed rule: case presentations are "as a rule not made"

Case presentations easily become a gateway to overselling exceptional data, and as a rule are not made. The exceptions are limited to alerting to adverse reactions, a small number of cases of a rare disease, and situations such as contrast agents that can only be shown through images (fictional model cases are treated the same). When made, cite the source, name competitors generically, do not emphasize or guarantee efficacy or safety, and do not extend from a case to an evaluation of the drug as a whole. At the top, in larger type than the body, place the note that "the presented cases are only a part and not all cases show the same result," and always record any adverse reactions.

06The items that show the drug's profile — pharmacokinetics, pharmacology, toxicity

(6) Pharmacokinetics

Record absorption, distribution, metabolism, and excretion (ADME) in humans. If there are no human data, animal and in vitro data may be carried as a supplement, labeled "(animal species)" and "(in vitro)." State the subjects (healthy people/patients, adults/children), and label foreign data "(foreign data)" in the title. Pharmacokinetics in special-condition patients — the elderly, those with renal or hepatic impairment, those on dialysis — may be recorded where reference data exist, and where there is support, a discussion of dose and interval according to organ function is allowed. But this must not turn into an emphasis on safety for these patients. For drugs requiring TDM, show the key parameters such as blood concentration, the principal elimination route, and drug metabolism.

(7) Pharmacology

Based on clinical and non-clinical pharmacology studies, record the pharmacological action and mechanism that support the approved indication. When results that deviate from the approved dosage are carried, the approved dosage must be noted alongside. Comparison with a control drug is fact only — no commentary — and the comparison must not be emphasized in titles or figures. For combination drugs, do not mislead about efficacy through the pharmacology of individual components, and show synergy only with objective data. Non-clinical data are labeled "(animal species)" and "(in vitro)" and must not emphasize or guarantee clinical efficacy or safety. A pharmacological action whose relation to the indication is unclear is shown as "reference information," without emphasis.

(8) Safety pharmacology and toxicity studies

Record safety pharmacology and toxicity studies on the central nervous, cardiovascular, and respiratory systems and so on, based on animal and in vitro results. As a rule, only the facts of the drug's own study results are given; competitors' products are not recorded. No expression that leads to emphasizing clinical safety is used. And — if there is knowledge of a pharmacological action or toxicity suggesting the possibility of an adverse reaction in the clinic, it must be recorded. Even when unfavorable, information on the cautionary side is not buried. Item (8) is where that asymmetric duty appears in its plainest form.

07The later items that carry practical detail and verifiability

Item (9), physicochemical properties of the active ingredient, presents the generic name, chemical name, molecular formula, structural formula, and the like as objective fact. Item (10), pharmaceutical matters, records stability and compounding changes as the facts of study results only, without evaluative words like "suitable for compounding." Item (11), handling precautions, sets out storage, shelf life, and expiry under small headings; for specified biological products, it states under the package insert that usage records are to be kept for at least 20 years. Item (12), packaging, is a short column but practical information that helps distribution and prevents mix-ups.

(13) Related information: leaving the facts of version and reimbursement on record

Record the approval number and date (additional approvals up to the latest), the NHI listing date, the launch date, approval conditions, notes on insurance benefits, and the publication dates of re-examination and re-evaluation results. Even the handling of blanks is prescribed — for example, if there is no information, the item name itself is not listed. None of this is flashy, but it is the information that lets one later trace "when, and under what conditions, the drug was approved."

(14) Principal references, (15) marketing authorization holder, (16) date of preparation or revision

Item (14) is the column showing the references that back up the entries: if the clinical results are approval-time evaluation materials, say so; for an original paper, give the bibliographic details; for internal material, write it so the specific content is clear. References relating to clinical results are also carried, with bibliographic details, on the relevant clinical-results pages. Item (15) is the name and address of the marketing authorization holder (including the reference-request and inquiry contacts); for a drug held under a foreign special approval, the name of the selected marketing authorization holder is given along with the holder's name and country.

→ Source page: Chapter 2: Comprehensive Product Information Summary

(1) Items to be stated on the cover

The comprehensive product information summary arranges sixteen items in a fixed, ordered format. At the very front—item ①—sits "Items to appear on the cover." Why the cover? Because it is the first page a healthcare professional looks at, the single sheet where the information that keeps a drug from being mixed up or misused must be confirmed at a glance. The Creation Guide constrains not only what goes here but how it must look. That level of detail may seem excessive, yet it is the physical implementation of the foreword's principle: convey accurately, without inviting misunderstanding.

01Why "fixed items" belong on the cover

Recall the spirit of the foreword. A Product Information Summary "complements" the (electronic) package insert and may not exceed the approved content by a single word. The cover carries the part of that approved content that identifies the drug, states its regulatory handling, and announces the dangers that must be told first. It is not a panel where the author picks what to show; it is where the reader receives, without omission, what must be checked. That is precisely why selection is not permitted and the items are fixed.

This idea runs continuous with the design philosophy of the whole Creation Guide. Even true statements can violate the rules if arrangement or omission produces a false impression. If an item is missing from the cover, the reader cannot tell whether it is "absent" or "forgotten"—and that ambiguity itself breeds misunderstanding. Fixing the items is the simplest way to prevent it.

02The basic elements on the cover

The basic elements placed on the cover can be organized into these five. Each serves to "uniquely identify the drug," "state its regulatory handling," or "state its status under health insurance."

• Japan Standard Commodity Classification number — given down to the detailed classification below the middle category, descending past broad strokes to the fine division the product belongs to.
• Therapeutic classification name — displayed as the product title; it must not diverge from the (electronic) package insert.
• Regulatory category — the applicable category (discussed below) is written alongside the name.
• Name — for products not listed in the Pharmacopoeia, the approved brand name with the generic name appended; for Pharmacopoeia products, the Pharmacopoeia name.
• Whether listed in the NHI drug price list — stated as listed or not.

How the name is written splits on "Pharmacopoeia or not"

Name notation is not uniform. The basis differs between products listed in the Japanese Pharmacopoeia and those that are not. The contrast below captures the difference in handling.

Even within the same "name" item, what counts as authoritative differs—whether you transcribe the fact of approval or follow the name in the official compendium. This gap shows that correctness of notation is always tied to a higher norm.

03The regulatory category is written in full alongside the name

The regulatory category tells how the drug is treated under law. Where applicable, the full text of that category is written together with the name. The categories concerned include the following.

• Specified biological product / Biological product
• Poisonous drug / Powerful drug
• Narcotic / Psychotropic / Stimulant / Stimulant raw material / Habit-forming drug
• Prescription drug
• Emergency approval / Special approval / Conditional approval

Why the full text rather than an abbreviation? These categories impose legal duties on the handler—restrictions on storage, recordkeeping, and dispensing. Abbreviations or omissions invite misreading and lead straight to overlooked obligations. Writing them in full on the cover is the safeguard that delivers the danger or restriction reliably "at first glance."

04Why the look of warnings and contraindications is constrained by numbers

The cover carries the full text of the (electronic) package insert's warnings and contraindications, divided into sections, placed in a conspicuous spot on the cover. And the way it must look is specified concretely.

The Creation Guide's character shows plainly here. It specifies not only content (carry the full text) but the "look"—font, point size, frame. A fact may sit on the page, yet if it is small and unobtrusive it does not reach the reader. The visibility specification is the mechanism that secures the foreword's "accurate, without misunderstanding" at the visual level.

When there are too many contraindications to make them stand out

Sometimes the contraindications are so numerous that conspicuous presentation is physically difficult. In that case the contraindications themselves are still carried, but the reason for setting each one may be omitted. This is strictly an omission of the reasoning, not a deletion of the contraindication facts. The core that bears on safety stays; the explanatory part yields space. The priority is visible right here.

05The post-marketing surveillance mark and the RMP notice

Another role the cover carries is to announce the product's current "surveillance status."

• A new drug subject to early post-marketing phase vigilance displays the unified mark on the cover for six months from launch. Right after launch, real-world data is still scarce and adverse-event information is being gathered intensively—the mark tells the reader so.
• A product with a Risk Management Plan (RMP) in place states "Risk Management Plan target product" on the cover.

06What it means to "decide even the look"

Across the cover's rules, one thing comes into view: the Creation Guide treats "how it looks" with the same weight as "what is written." The same fact lands differently depending on placement, size, and color. Efficacy large and prominent, safety small and faint beside it—this is not a lie, but it gives a false impression. The cover's numerical specifications (10 points or larger, Gothic, framed) exist to structurally block that kind of "true but misleading" presentation.

It connects to the discipline of science. Evidence can be made to look more or less than it is by how it is emphasized. The Creation Guide constrains appearance to keep the reader able to weight information correctly—held in place by mechanism, not left to the author's goodwill. The cover is that idea in miniature.

→ Source page: (1) Items to be stated on the cover

(2) Development history

The "Background to Development" column tells the story of why a drug came into being and what path it travelled to reach the market. It is not a table of data, nor a declaration of efficacy. It is the place where a narrative lives. And precisely for that reason, the pen slips here more easily than anywhere else. The more the background is told, the more the writer's attachment seeps in, and before long the line between "hope" and "the approved fact" begins to dissolve. The Creation Guide places several restraints on this column for one purpose: to let the freedom of storytelling coexist with the facts of approval.

01What this column may contain

What may be placed here is the background that led to development, the development process, the clinical positioning, and the approval and marketing status overseas. Why the drug was needed, which unmet need it sought to answer, what knowledge accumulated along the way of development — such context can be handed to the reader.

Conversely, this is not the place to restate "indications" or "dosage and administration". Background is written as background; the substance of the approval follows the wording of the approval columns. To paraphrase the approved scope in a narrative voice is to deviate from what the background column is for.

"Background" and "promotion" are a hair apart

Describing an unmet need is one thing; implying that one's own product is the sole answer to it is another. A background account is a map that helps the reader understand where the drug sits, not a device for imprinting a conclusion in advance. Keep the map accurate, and leave the conclusion to the reader.

02Do not mislead about domestic approval

This is the heaviest restraint. The background column may touch on overseas approval status and marketing record. But it may do so only so far as it does not mislead the reader about the scope approved domestically.

It is not unusual for a new drug to have different approved indications or dosing from one country to another. A drug with a broad indication abroad may be permitted only within a limited scope at home — this happens routinely. If the background column parades a glittering overseas record yet stays silent on the domestic limits, the reader mistakes the overseas scope for the domestic one. That is precisely a "description that misleads about domestic approval".

Same fact, different impression

A sentence that is true as fact can still mislead by how it is placed. Below is an example in which not a single statement is false, yet the impression shifts sharply.

A qualifying (restrictive) wording refers to conditions attached to the indication at approval — for instance prior-treatment history, concomitant-use conditions, or limits on the target patient population. Strip these out so the drug reads as broadly applicable, and even if each sentence is true, the whole invites misreading. The same discipline that forbids widening a "pre-specified scope" after the fact in the world of evidence is at work here too.

03The manner of referring to existing drugs

To tell the story of development is often to mention existing treatments or predecessor drugs. That in itself is not forbidden. The problem is tone. Writing that belittles existing drugs in order to make one's own product stand out — disparagement of others — is not permitted.

A comparison carries meaning only when it is made fairly, by a verified method. If, within the flow of a development narrative, a predecessor is dragged down by thinly grounded contrasts or impression-steering, that is not comparison but disparagement. What the reader needs is not how "relatively superior" one's product can be made to look, but an accurate coordinate of where it sits among treatment choices.

04How to handle "improved safety"

Many drugs are developed with improved safety as their main aim — reducing the adverse effects of existing treatment, achieving a more manageable route of administration. Such motives may be written in the background column, because they are the heart of the development story.

There is a boundary, however. Stating as background that a drug "was developed to improve safety" is an entirely different claim from emphasising or guaranteeing that it "is safe". The former describes the intent of development; the latter asserts the result.

Why safety alone is held to a stricter line

Efficacy can be claimed, with conditions, as a value; but statements about safety have a strong power to lower the reader's guard. Read "safe", and people relax their caution. So expressions concerning safety are required to be accurate, including unfavourable information, and assured phrasing is warned against in particular. In the discipline of science, too, the principle is to disclose safety information even when it is unfavourable to oneself. The restraint "do not turn it into emphasis or guarantee" carries that principle into the context of the narrative.

05What the restraints really are — why bind it this far

Read the rules of the background column one by one, and a common design philosophy emerges: precisely because it is a column for telling a story, restraints are placed so that it does not drift from the facts of approval.

The indications and dosing columns are bound to the very wording of the approval, so there is little room to deviate in the first place. The background column, by contrast, has high latitude. Background, process, positioning, overseas status — the material it may carry is broad. The wider the latitude, the wider the entrance to misunderstanding. So individual prohibitions are layered on (avoid misleading about domestic approval, no disparagement of others, no emphasising of safety) to keep the narrative from leaving the gravitational field of fact.

This overlaps with the stance set out in the foreword — that even areas without explicit wording are governed by higher norms. The material that may go into the background column is diverse, and no set of articles could enumerate it all. That is exactly why understanding the principle behind each prohibition — do not drift from approved fact, do not create misunderstanding, disclose what should be disclosed even when unfavourable — supports judgement in situations the text does not spell out.

→ Source page: (2) Development history

(3) Characteristics

01What the "Features (Characteristics)" section is for

Placed third in the comprehensive product information summary, the "Features (Characteristics)" section is where a drug's identity is impressed on the reader in a few words. It comes right after the development history (②) has set the background, and just before the clinical results (⑤), the heavy chapter of evidence. In other words, it sits at the point where the outline of the drug is handed over before any detailed figures have been shown. That is exactly why writers are tempted to compress: "in short, this is what the drug is."

That temptation to compress is the source of the danger. The reason the Creation Guide singles this section out and warns that it is the section most prone to exaggeration is structural: it tends to become the place where the conclusion is pre-empted and stated flatly. The shorter the assertion, the easier it becomes a claim severed from its evidence.

02Balancing efficacy and safety — why one side alone is a violation

In the features section, if you speak of efficacy you must present safety in the same place, in balance. This is not a matter of mere appearance. The duty the foreword raises — to convey accurately without misleading — has two layers: the duty not to lie, and the duty not to mislead. Even if every individual statement is factual, lining up only efficacy and pushing safety off to the margins forms in the reader's mind the image of "a drug that works with little danger" — an image different from the sum of the facts. This is the textbook case of "factual yet misleading," the gap the Creation Guide consistently seeks to close.

So the features section avoids the emphasis or guarantee of safety with the same severity it avoids false or exaggerated efficacy. Flat assertions such as "few side effects" or "highly safe," even when they capture one face of the data, are forbidden because they turn safety into a selling point. Safety is the object of an asymmetric duty — to be disclosed even when unfavorable — not a favorable sales line.

03Not a single step outside the approved scope

The efficacy and usage that may be written as features are confined to the approved indications and dosage, and the so-called qualifying (restrictive) wording (qualifying conditions such as "only when ○○ is ineffective or inappropriate") must be reflected accurately without omission. In a short feature sentence the qualifying condition is exactly what one wants to drop, but removing the limit turns it into the description of a different drug.

At the same time, the features section must not conflict with the warnings and contraindications. To state on the cover the patients who "must not use" the drug, yet give in the features section a broad impression as though such patients were included, sets the most important safety information against the body text. Because the reader carries forward the impression of the features seen first, this contradiction readily leads to real harm.

04If you assert it, put the basis inside the same material

If you touch on efficacy or safety as a feature, place the supporting results inside the same material and note the page. This is how the guide's pillar of structurally guaranteeing verifiability appears in the features section. Since a feature pre-empts the conclusion, you must always provide a route by which the reader can check that conclusion. If you write "it works," build a bridge by page number to which trial's which figures justify saying so.

Confirmatory analysis, or a nominal p-value?

When touching on efficacy in the features section, make clear whether the claim rests on a confirmatory analysis result or on a nominal p-value. A confirmatory analysis that confirms a single pre-specified primary hypothesis and a nominal p-value (any p-value derived from analyses other than pre-specified confirmatory analyses) bear entirely different weight as conclusions. Promoting a nominal p picked from a post-hoc analysis or subgroup into a feature, as though it were a verified effect, is a misstep down the evidence hierarchy.

05Comparison with other companies' products — the permitted range and the ban on evaluation

Touching on a comparison with another company's product in the features section is not itself forbidden, but the permitted range is narrow. If you mention a comparison, state the trial title, and you may show only the result of the primary endpoint (the confirmatory analysis item). You cannot speak of superiority by picking up secondary items or post-hoc figures.

Moreover, you must not add evaluation or commentary on the other product's results. Presenting figures as fact is one thing; laying meaning or a judgment of superiority over those figures is another. The latter touches the ban on disparagement. Name the other company's product by its generic name; do not identify it by brand name.

06How to write safety — consistent with the package insert, and no control-drug side effects

When touching on safety in the features section, keep it consistent with the (electronic) package insert, state the serious side effects and the main side effects, and note that the (electronic) package insert and the clinical-results safety data are to be referred to. Do not build a material-specific picture of safety; act as a window onto the approved safety information.

Here a brake specific to the features section applies. Do not record the side effects of placebo or the control drug.

07Do not link animal or in vitro data directly to the clinic

When touching on non-clinical findings in the features section, mark animal results with "(animal species)" and in-test-tube results with "(in vitro)", and do not link them directly to clinical efficacy or safety. Given differences in species, dose, and system, animal or in vitro findings cannot pre-empt a conclusion in humans. In the evidence hierarchy, peer-reviewed clinical research sits above; non-clinical work is placed below. Blur the source in the assertion-laden features section, and the reader mistakes a preclinical finding for a clinical fact.

08Brakes on charts and tables (detailed rules)

When a chart accompanies the features section, the manner of presentation itself is constrained. Each rule blocks "letting the same data form a different impression through presentation."

Do not turn a small number of cases into a percentage or graph

When the number of cases is under 10, do not graph the response rate or use a % notation; show it as an actual count (●cases / ■cases). Writing 2 of 3 cases as "66.7%" erases the smallness of the denominator and makes the figure look robust. Because a proportion from few cases swings widely by chance, an actual count is the only way to convey the uncertainty to the reader honestly.

Hazard ratio and risk reduction rate when there is no significant difference

When there is no significant difference between groups, the hazard ratio itself may be stated, but the risk reduction rate must not be stated from it. No significant difference means the direction or size of the effect does not exceed the range of chance. Translating that into "an ○○% risk reduction" presents an unconfirmed effect as a definite benefit. A hazard ratio is an index to be read together with its confidence interval and the absolute difference — not a tool for asserting a benefit on its own.

09"Significance ≠ clinical meaning" — to be kept in mind precisely here

Because the features section hands the reader a value judgment, a flat claim that mistakes the meaning of statistics does the most harm here. In a large trial, even a clinically tiny difference can become statistically significant; conversely, the absence of a significant difference is no proof of "equivalence." A feature sentence that swaps "it was significant" for "clinically meaningful," or "no significant difference" for "equivalent," states facts throughout yet breeds misunderstanding. Do not assert merely "it works" while leaving outside the section the context that matters — the range of effect shown by the 95% confidence interval, the size of the absolute difference.

→ Source page: (3) Characteristics

(4) Product information

Of the sixteen items that make up a Comprehensive Product Information Summary, the fourth is the product information section, commonly called product information (DI). The development history tells the backstory; the features and clinical results present the heart of the efficacy claim. Right after these comes this section. The order carries meaning. Just behind the narrative and the appeal, a window is inserted that gathers the approved facts themselves, pulling the reader back to the official record. This is the spot in the material that sits closest to the (electronic) package insert.

01Why place an "approved-information window" inside the material

The foreword makes it explicit: the basis for proper-use information is the (electronic) package insert, and Product Information Summaries merely supplement it. That single word, supplement, does a lot of work. The Product Information Summary sits below the (electronic) package insert; the approved content is the original. So a material can never step even one character beyond the scope of approval.

Yet if a healthcare professional, holding the material, had to track down a separate (electronic) package insert every time to learn the correct usage, the duty to "convey accurately" would not be met. So a single window summarizing the approved information is placed inside the summary. That is the DI section. The material is not a substitute for the (electronic) package insert, but it builds one reliable bridge to it. Without this bridge, the attractive wording of the features section could end up walking off on its own.

In other words, this section is also a device for cooling the heat of the pitch. By lining up the immovable facts — regulatory category, indications, dosage and administration, warnings, contraindications — right after the pages that sell efficacy, it draws the reader's understanding back inside the frame of approval.

02What "follow the latest (electronic) package insert" really means

An (electronic) package insert is not a static document. As safety knowledge accumulates, warnings are added, contraindications widen, and adverse-reaction entries are updated. A drug's safety information moves most dramatically after launch. Merely copying the (electronic) package insert as it stood the moment the material was printed can leave it outdated six months later.

So this section must be grounded in the latest version of the (electronic) package insert available at the time of preparation. A convenient phrase from an old version, or recycling a draft used before, is fatal here. The freshness of the safety information is what decides the quality of this section.

03Detailed rules: how to place the revision notice at the top

State "stay fully alert to revisions" in a prominent position

At the top of the relevant page of this section, place a sentence to the effect that one should stay fully alert to revisions of precautions information, including warnings and contraindications, in a form that will not be overlooked. It is not mere boilerplate. The material is fixed in time as a printed object, but the (electronic) package insert moves — this notice exists to warn the reader of that time gap in advance.

"The wording in this material may differ from the (electronic) package insert you are reading right now. The final basis is the (electronic) package insert." That, in essence, is what the opening sentence says. It is a declaration that lowers the material's own authority by one notch and yields to the original.

State the preparation or revision date

As of when does the (electronic) package insert that was followed stand? Stating the preparation or revision date answers that. Without a date, the reader cannot judge whether the material's information is new or old. Only with the date can one verify that "this material is based on the (electronic) package insert of the such-and-such version."

This resonates with the very last of the sixteen items, Item 16, "Date of Preparation or Revision." Again and again the Creation Guide forces a record of "as of when." Keeping the version on record, preserving a state in which it can later be verified and recalled — the accumulation of that quiet discipline is what supports the material's trustworthiness.

04A design that blocks "true but misleading"

One implication of the foreword is the point that the duty not to lie and the duty not to mislead are separate. Even if every entry is factual, it is a violation if the manner of presentation lets the reader form a mistaken image. The DI section is no exception.

For instance, if the revision-notice sentence is pushed into a corner in type far smaller than the body text, on paper it counts as "stated." In substance, it goes unread. The Creation Guide's instruction to make it "prominent" exists to block this kind of formal box-ticking. Not only what is written, but how it is shown, falls within the reach of the rule.

05Consistency — relations with other items and norms

The DI section does not stand alone. It must be consistent with the cluster of items that handle the same approved facts from other angles: the warnings and contraindications on the cover (Item 1), the safety entries in clinical results (Item 5), the approval dates in related information (Item 13), and the principal references (Item 14). A mismatch in which only the window is old, or only the cover is new, erodes the trust of the whole.

The foreword further states that the Creation Guide covers basic matters, not everything, and that matters outside its provisions still fall under the Pharmaceuticals and Medical Devices Act, the Standards for Fair Advertising, the sales-information-provision activity guideline, and the JPMA Code. Even when you hit a question about DI wording that the Creation Guide does not spell out, "not written down" does not mean "free." You return to the higher norms and to the original-respecting spirit of supplementation to decide.

→ Source page: (4) Product information

(5) Clinical results

Clinical results tend to be the longest section in any promotional material for prescription medicines, and at the same time the easiest to misread. The numbers a trial produces are neutral in themselves, but the impression they leave swings widely depending on which trials are chosen, which endpoints are put forward, and how the figures are drawn. The spirit set out in the foreword — that the electronic package insert is the original and these materials only complement it, that one must avoid not only falsehood but misunderstanding, and that areas without explicit rules are still governed by higher principles — is tested most severely here. What follows explains not only what may be shown, but why, tying each requirement to the hierarchy of evidence and the discipline of statistics.

01Where the trial data may come from

There is a gatekeeping question at the entrance. Not every result on hand may be used. Clinical trial data cited in materials must originate from one of the following.

• Data evaluated during the domestic approval review
• Material assessed as the basis for a revision of the electronic package insert
• Original papers that have passed rigorous peer review (conference-presentation data and review articles do not count)
• Material evaluated as part of a re-examination application

What these four share is that each has passed at least once through a checkpoint of third-party verification. Peer review, approval review, re-examination — all are mechanisms that curb the temptation to line up only the convenient results. Conference data and reviews are excluded because they carry the marks of early reporting and an author's interpretation, and differ in nature from settled primary evidence. The idea here is that evidence comes in a hierarchy, and the denser the verification, the more fitting the data is as a foundation for materials.

Comparative trials and real-world evidence

What may be cited as a clinical comparative trial is a double-blind trial, a randomized trial, or material assessed during approval review as a substitute for double-blinding. Blinding and randomization are design defenses against the expectations of observers and patients leaking into the data; they are the backbone of a result's reliability.

For real-world evidence (RWE), whose weight has been growing, use it only when all four of the following conditions are met.

RWE reflects actual practice, but it is prone to imbalances in patient background and to confounding. That is precisely why a double brake is required: read it alongside the confirmatory trial that forms the main basis, and put its limitations up front rather than hiding them. Do not let an observational study appear to be decisive evidence on the same footing as a randomized trial — that is the heart of these conditions.

02The presentable range — do not step beyond approval

The principle is plain: results are presented within the approved range. Even for a drug whose dose may be adjusted as appropriate, efficacy data above the approved dose are not shown. Nor are trial data that conflict with the starting dose or the method of adjustment. Figures that do not match the approved usage, however favorable, would mislead actual clinical use.

Annotations when data include off-label elements

Where off-label information cannot be avoided, a discipline of explicit labeling applies.

• A dose-finding study that includes an off-label dosing arm must be labeled clearly as a "dose-finding study", with the approved usage annotated.
• When presenting results that include off-label elements, place at the head a note stating that part is off-label and the reason for inclusion, and annotate the corresponding indication and usage.
• For data that include deviating cases, add a note that the data have been limited to cases within the approved range and partly modified, together with the reason for deletion.
• Results whose dosing arms contain off-label cases must not be re-analyzed.

The line "must not be re-analyzed" matters most. To remove off-label cases and rebuild the numbers is to produce not the result the trial showed, but a different result made by the author of the material. The wariness toward altering, after the fact, an analysis plan that was specified in advance is what shows through here.

Control-drug usage and subgroups

Confirm that the dosage of the control drug falls within the approved range of every country that took part in the trial. If domestically off-label information is included, annotate the domestic approved usage; if the drug is not approved domestically, say so. Readers read in the domestic clinical setting, so the care taken is to keep them from misreading numbers based on foreign standards.

03The opening caution and the required items

At the top of the first page of clinical results, in a point size larger than the body text, place "For warnings, contraindications, etc., see page ○○." Before reading favorable results, the reader is turned toward the premise of safety — a concrete expression of the stance that these materials complement the electronic package insert as the original.

Items each trial cannot do without

For every trial, show the following elements, neither too little nor too much.

The point of "making confirmatory analysis items clear" connects directly to the efficacy section below. Planting a flag at the outset for what the trial concluded, and on what basis, is what prevents later exaggeration.

04Efficacy — separate confirmatory results from nominal p-values

Efficacy is shown according to the trial design, with the positioning of endpoints stated. The core discipline is to distinguish confirmatory results from results that rest on nominal p-values alone. Only an analysis specified in advance as a primary endpoint, with statistical error controlled, can be called "confirmed." A p-value computed exploratorily carries no more meaning than proposing a hypothesis, even if it falls below 0.05. Mixing the two leads the reader to mistake a secondary finding for an established effect.

That a difference is statistically significant and that the difference carries clinical meaning are two different things. To hold up "significant" alone, without the size of the difference, the width of the confidence interval, and the weight of the endpoint, is an attitude that keeps the numbers from speaking rather than letting them speak.

05Safety — the requirements change by column

Safety descriptions, even for the same drug, demand different things depending on the column. In the safety column of clinical results, show, for both the drug and the control (including placebo), the event names, the number of cases, and the incidence rates. For serious adverse reactions including death, and for those leading to discontinuation, record the event names and the number of cases.

Operations that "emphasize" safety are also forbidden. One does not stage safety by, for instance, presenting a significance test where there is no difference from placebo. For the control drug, present only the facts, adding no evaluation or commentary. Furthermore, unless an item is both a primary endpoint and confirmatory, do not present between-group significance tests or confidence intervals (showing the estimate for each group is acceptable).

Contrast with the product-features column

Even for the same safety topic, the column describing a product's features does not state the control drug's adverse reactions. This is the mirror image of the clinical-results column, which lays out the events of both drugs side by side for fairness. When the column's purpose differs, so does what is shown and what is held back. Borrowing content across columns without noticing this contrast steps outside the discipline.

06Reference information and case presentations

Reference information

Results obtained secondarily within the approved range are set apart from the proper efficacy evaluation as "reference information." For each trial result, state explicitly that it is reference information, and do not let the indication or effect be misunderstood. Keep the title to an expression that does not assert and emphasize an action, such as "Effect on ○○." This is a partition that keeps a secondary finding from being read, before one notices, as if it were the main effect.

Case presentations

Individual case presentations, because they readily lead to the emphasis of exceptional data, are as a rule not created. The exceptions allowed are limited to the following.

• Cautions regarding adverse reactions
• Rare diseases and other settings where only a small number of cases can be obtained
• Contrast media and the like, where matters can be shown only by images (fictional model cases are treated the same way)

Even when created as an exception, state the source and name other companies' products by generic name. Do not emphasize or guarantee efficacy or safety. Do not evaluate or comment on the drug as a whole from that one case. And at the head, in a point size larger than the body text, place a statement that the presented cases are only a part and that not all cases show the same result, and always record any adverse reactions. It is a structural device to keep the vividness of a single case from governing the impression of the whole.

→ Source page: (5) Clinical results

(6) Pharmacokinetics

The sixth section of an integrated product information summary, "Pharmacokinetics," describes how a drug behaves once it enters the human body. It covers absorption, distribution, metabolism, and excretion, abbreviated ADME from the first letters of each. Where the clinical results chapter asks whether the drug works and whether it is safe, pharmacokinetics explains the other side: why the dosage takes the form it does, and why caution is warranted in particular patients. An approved regimen of so many milligrams so many times a day rests on observations of how blood concentration changes over time. This section is where that observation is shown honestly.

01Presenting ADME: human data as the rule, animal data as supplement

The core of the record is human absorption, distribution, metabolism, and excretion. Blood concentrations measured in healthy adults or patients, half-life, volume of distribution, metabolic pathways, and excretion rates are set out. Why are human data the rule? Because the evidentiary discipline of the opening chapter operates here too. Animal experiments and in vitro studies must not be carried directly into human practice, given differences in species, dose, and experimental system. The same applies to pharmacokinetics: where a value can be measured in humans, the human value is what should be shown.

Even so, depending on the stage of development, some items may not yet have human data. Only in that case may animal or in vitro results be included as a supplement, and not without conditions. Results using an animal species must carry (species name), and test-tube results must carry (in vitro). These are markers so the reader never mistakes the figure for a human value. Animal data without such a marker, even when factually correct, lead the reader to form a false picture. The opening chapter's distinction between the duty not to lie and the duty not to mislead appears here intact.

02Stating whose data these are: labeling the study population

For the same drug, behavior changes with whom it was given to. This section therefore must distinguish the study population every time.

Healthy subjects or patients

Results from a Phase I dose in healthy adults differ in character from results in patients. Healthy-subject data suit observing the drug's intrinsic behavior, but the metabolic and excretory conditions of actual patients can differ. Without stating which population produced a value, the reader misjudges its range of application.

Adults or children

Children differ markedly from adults in metabolic capacity per body weight and in body-fluid volume, so their kinetics diverge. Whether adult data can be applied to children requires careful judgment, which makes stating the target age range indispensable.

Labeling foreign data

Results obtained in foreign subjects carry (foreign data) in the title. Racial differences can alter the activity of metabolizing enzymes and the course of blood concentration, so the values may not transfer unchanged to domestic patients. Presenting overseas figures as continuous with domestic data again touches the duty not to mislead.

03Departures from approved dosage must accompany the approved values

Pharmacokinetic studies sometimes yield results measured under dosing conditions that differ from the approved regimen, such as during dose-response investigation or under different overseas regimens. When such deviating data must be included, the rule is to state the approved dosage alongside them.

The reason lies in the brake of the approved range. A Product Information Summary may not exceed the approved content by a single point. Showing only the blood concentration from a deviating condition risks the reader taking it as the value obtained under standard use. Placing the approved value next to it conveys the boundary: this is not a result under the approved regimen. The thinking matches the clinical results chapter, which requires off-label data to declare at the outset that they are off-label and why. It is an annotation to keep the boundary from blurring.

04Patients with special conditions: recordable, but not turned into a safety guarantee

The elderly, those with renal or hepatic impairment, patients on dialysis. In such special conditions, drug elimination may slow and blood concentration rise, or behavior may diverge from expectation. This is among the information clinical practice most wants.

Recordable when reference data exist

Pharmacokinetics in these populations, and interactions under special conditions, may be recorded where reference data exist. Further, where the backing is firm, explaining dose or interval adjustment according to the degree of organ function is also permitted, such as practical guidance on how to reduce the dose of a renally excreted drug when renal function declines.

Yet it must not read as "safe in these patients too"

Here a brake applies. Being able to explain the kinetics of special-condition patients does not license converting that into an emphasis on safety, as if to say the drug can be used safely in these patients. Kinetic values only show how the drug moves in the body; they do not guarantee safety itself. If anything, slowed elimination often signals a risk of accumulation. Swapping the presentation of data for a safety appeal is the textbook "true but misleading" the opening chapter warns against.

05Linking to precautions information, and TDM

Specific cautions on the same page or spread

When the precautions information of the (electronic) package insert sets out a specific caution related to pharmacokinetics (for example, a particular patient requiring dose reduction, or a co-administration that changes concentration), and it is judged especially necessary, that relevant caution is placed on the same page or facing spread as the pharmacokinetic record. If data and caution sit apart, the reader sees only the value and overlooks the caution. Setting them physically side by side prevents misunderstanding at the level of how things are seen. It is the same design instinct as placing cover warnings and contraindications, in gothic type at a specified point size, in the first field of view.

Drugs requiring TDM need their key parameters

For drugs requiring therapeutic drug monitoring (TDM), proper use is tied directly to managing blood concentration. For such drugs, key parameters such as blood concentration, the main elimination pathway, and drug metabolism are recorded. Where dose is adjusted on the basis of blood concentration, these values govern the prescribing decision itself. Once the kinetic figures bear directly on clinical decision-making, the section's role goes beyond mere reference and becomes information that supports safe use.

→ Source page: (6) Pharmacokinetics

(7) Pharmacodynamics

01What the pharmacology section is for

In product information material, the pharmacology section explains why the drug works. Drawing on clinical pharmacology studies and non-clinical studies, it sets out the pharmacological actions and the mechanism of action that support the approved indication. Order matters here. The pharmacological claim does not come first; the observed study results come first, and the text then explains how those results support the approved indication. Reverse that order and you are left with a persuasive story of "it seems to work" with no data underneath it.

As the foreword establishes, a Product Information Summary complements the (electronic) package insert and must never contradict it. The pharmacology section answers to the same spirit. Write the pharmacology that grounded the approval, within the range that was actually observed, without exaggeration and without inviting misreading. That is the destination.

02Clinical and non-clinical — two sources, two sets of rules

The evidence for pharmacology falls into two broad streams: results obtained in humans from clinical pharmacology studies, and results obtained in animals or in vitro from non-clinical studies. Because their evidentiary weight differs, the rules for presenting them differ too.

When clinical pharmacology goes in the clinical results section

Clinical pharmacology results may, where appropriate, be placed in sections such as clinical results. But a condition attaches: the wording must not become an emphasis on safety. You may not borrow the pharmacology discussion to plant, ahead of time, an impression such as "few adverse reactions." Safety belongs in the safety section, shown fairly and including unfavourable information, and pharmacology must not become a back door for safety appeals.

Non-clinical must be flagged as "not about humans"

When non-clinical results are presented, always state the animal species used, as "(animal species)," or for an in vitro system, as "(in vitro)." The reason is simple: an action observed in animals or in vitro does not, on its own, guarantee efficacy or safety in humans. Different species have different metabolism and different receptors. The notation is honesty toward the reader and a brake on over-interpretation. Using non-clinical data to emphasise or guarantee human efficacy or safety is not permitted.

03Population and overseas data — whose results, obtained where

"It worked" means different things in a healthy volunteer and in a patient. So when stating clinical pharmacology, specify the population: healthy persons or patients, sex, adult or paediatric. The reader uses that classification to judge whether it applies to the patient in front of them. Omit the classification and you make the scope look broader than it is.

Results obtained abroad carry the note "(overseas data)." Differences in ethnicity and medical setting can change how a result should be read, and above all the data must not be mistaken for the very basis of domestic approval. Showing the origin does not demote the data; it hands the reader the material needed to weight it correctly.

04The discipline of comparison — facts only, on equal terms

Nothing in pharmacology invites misreading more easily than comparison. Comparison is powerfully persuasive, and mishandled it becomes an implied claim of superiority. Several clear fences stand here.

Comparison with a control: facts only

If results comparing the drug with a control are shown, state only the facts. Add no commentary. Do not use the title or the design of figures and tables to emphasise the comparison. Staging the axes, colours or headings so the reader concludes "this one is better" is not presentation of fact; it is steering.

Comparison with other drugs requires the same approved indication

Comparison with other drugs, including competitors' products, holds only when both carry the same approved indication. Lining up drugs with different indications is not a comparison; only an apparent ranking remains. The same applies to non-clinical comparison: both must stay within the range of pharmacological actions that support the approved indication. Further, results from another company obtained in a comparative study are not to be carried into one's own material.

Stay inside the approved dosage and administration

If you present results obtained under conditions deviating from the approved dosage and administration, you must also state the approved dosage and administration. Dosages used in comparison must stay within the approved range, with both sides placed fairly. Running only one side at a favourable dose is not an equal comparison.

05Combination drugs and antibacterials — specific rules

Combination drugs: the pharmacology of each component, without misleading

The pharmacology of a combination drug is written from the pharmacological action of each individual component. On that basis, the requirement is not to mislead about the combined indication. In particular, any claim of synergistic action is allowed only when objective data exist. Avoid "add them together and of course it gets stronger" reasoning and any unsupported claim of synergy.

Antibacterials: do not stray outside the approved range of species

For antibacterials, whether standard strains or clinical isolates, if species outside the approval are included, say so. Keep the species and diseases described within the approved range. Lining up activity against unapproved organisms as if it were ordinary risks suggesting off-label use.

06Handling reference information, and disclosing conflicts of interest

A pharmacological action whose relationship to the indication is unclear is positioned as "reference information" and not emphasised. Push it to the front as if it were grounds for efficacy and you make something unconfirmed look confirmed. In comparative studies, even as reference information, competitors' results are not carried over.

And when citing studies or literature in which one's own company was involved, state the conflict of interest (COI) together with the bibliographic details. Who funded and who took part in the research is prerequisite information the reader needs to gauge the weight of the result. Not hiding it is what sustains trust in the data.

→ Source page: (7) Pharmacodynamics

(8) Safety pharmacology and toxicology

Among the sixteen items of the comprehensive product information summary, item ⑧ covers "safety pharmacology studies and toxicity studies." It records the results of safety pharmacology studies on the central nervous, cardiovascular, respiratory and related systems, together with toxicity studies, based on findings from animal experiments and in vitro work. What defines this item is that it deals not with human clinical data but with preclinical facts. Because of that, the writer faces two opposing pulls at once. One is restraint: results from animals or test tubes must never be told as if they guaranteed efficacy or safety in humans. The other is disclosure: if a sign that the drug could cause an adverse reaction in humans is visible, that information must be stated even when it is unfavorable.

01Why this item handles only preclinical data

Safety pharmacology and toxicity studies examine, before a compound is ever given to humans, what effects it exerts on which organ systems, using animals and cultured systems. For the central nervous system this means behavior, body temperature and seizures; for the cardiovascular system, blood pressure, heart rate and electrocardiogram waveforms; for the respiratory system, respiratory rate and ventilation — systems tied directly to survival. These differ in origin from the efficacy and safety results of clinical trials. Whereas item ⑤ (clinical results) deals with facts observed in humans, item ⑧ is the record of looking ahead, before human use, for where in the living body danger may lie.

The foreword positions the Product Information Summary as a "complement" to the (electronic) package insert, holding that the original source of proper-use information is the approved content itself. The preclinical data in item ⑧ cannot step outside this frame either. The mechanism of action or the picture of toxicity seen in animals is placed as objective fact, only within the range consistent with the approved indication and safety description. This is not a place for telling a story.

02The constraint of "facts about this drug only"

In item ⑧, as a rule only the factual results of the drug's own studies are recorded. Data on other companies' products are not brought in. In the preclinical domain, results swing easily with differences in test system, animal species and dose design, so the moment another agent is placed alongside, the impression that "ours is safer" starts to travel on its own. A comparison that ignores species and system differences runs against both the prohibition of disparagement and the prohibition of exaggeration or misleading impressions in Chapter 1. So this item does not set up the very structure of comparison.

Why other companies' products are not written here

In the safety column of item ⑤ (clinical results), the names, case counts and incidence rates of events for the control (including placebo) are required alongside the drug's own. A control group compared in humans under the same protocol carries meaning for reading the drug's safety. Preclinically the situation differs. Animal-study data from other companies offer no guarantee that species, dose and observed endpoints are aligned, so placing them side by side yields no fair comparison. With the same word "safety," the treatment reverses between item ⑤ and item ⑧. This difference comes from the different purpose of each column.

03Disclosure even when unfavorable — an asymmetric duty

The heaviest element in item ⑧ is the duty of disclosure. If preclinical work has yielded a pharmacological action or toxicity finding that suggests the drug could cause an adverse reaction in humans, it must be recorded. Even if that information is unfavorable to the product, suppressing a safety-side finding is not permitted.

This is the purest appearance of the asymmetric duty that the foreword runs through the whole Creation Guide: safety is disclosed even when it is unfavorable. Efficacy, so long as it is not exaggerated, leaves latitude in how it is written. But a sign on the safety side is not something a writer may erase for convenience. If concern for the cardiovascular system or toxicity in a particular organ is visible preclinically, that fact becomes material for the clinic to judge dose and patient selection. A few lines in item ⑧ support later safe use.

How to judge a "suggestive finding"

The axis of judgment is whether the preclinical finding could link to an adverse reaction in humans. Electrocardiographic changes seen in animals, central depression, or tissue changes in a particular organ, for instance, may lead to a clinical caution. In the hierarchy of evidence, animal and in vitro work sit at the bottom layer and cannot be tied directly to the clinic because of differences in species, dose and system. But "cannot be used as a guarantee of benefit" and "disclosed as a sign of danger" are separate matters. The weakness of the evidence weakens the grounds for reassurance, yet it is no reason to erase a warning. Here too the asymmetry in the direction of evidence is at work.

04Connections with other items

Item ⑧ does not stand complete on its own. If toxicity or a pharmacological action seen preclinically leads to a human caution, it must be consistent with the warnings, contraindications and important precautions of the (electronic) package insert. Whereas item ⑦ (pharmacology) handles "pharmacological action that supports the approved indication," item ⑧ handles "pharmacology and toxicity viewed from the safety side." The two are front and back: the same preclinical data read for different purposes. The convention of marking the species as "(animal species)" and in vitro work as "(in vitro)" so as not to tie them directly to the clinic is shared between items ⑦ and ⑧.

Then item ⑭ (main references) and item ⑯ (date of preparation or revision) attest to the origin and version of this preclinical data. Preclinical findings, too, become trustworthy information only when placed within the structure of verifiability — a cited source and a preparation/revision date. Item ⑧ is best understood not as a collection of showy prohibitions but as the item that enforces a single duty, "disclose even when unfavorable," at the most upstream point: the preclinical stage.

→ Source page: (8) Safety pharmacology and toxicology

(9) Physicochemical data on the active ingredient

This is the quietest field in the package insert. Unlike efficacy or dosage, it does not directly move a clinical decision; unlike a boxed warning, it does not stop the reader in red type. There is a nonproprietary name, a chemical name, a molecular formula, a structural diagram. For a radiopharmaceutical, nuclear physical properties are added. In short, this field states, as plain objective fact, what the drug is as a chemical entity. Precisely because it is unglamorous, whether it is written correctly determines the foundation of trust for the whole document.

01Why "identity" deserves its own field

If the identity of the active ingredient wavers, every record built upon it — pharmacology, pharmacokinetics, safety — floats free. Clinical data become meaningful only once it is fixed which molecule is being discussed. This field is therefore like the foundation piling that supports the building. It never shows in the facade, but if it is bent, every floor above tilts.

In the spirit of the foreword, the electronic package insert is the original record that speaks for the product, existing to complement the reader's judgment. Complementation presupposes that the subject is unambiguously fixed. Pinning the molecule to a single point through nonproprietary name and chemical structure is this field's role — the "fixing of the subject" for all that follows.

02The listed elements and their differing roles

Even among "names," the nonproprietary name and the chemical name serve different functions. Settling for one of them lets information fail to reach some classes of reader.

Because each element covers a different range, identity becomes three-dimensional only when they are present together. A name alone drops the salt or hydrate distinction; a structure alone is not the shared language of search and prescription.

03The nonproprietary name — the molecule's address, independent of the brand

A brand name is the seller's word; the nonproprietary name is the molecule's own address. Even when several generics appear, even when foreign literature is consulted, the same name reaches the same molecule. This field places the nonproprietary name first so that the reader is handed, at the outset, the entrance for connecting the document to outside knowledge — textbooks, papers, the inserts of other drugs.

Leave no variation in notation

Where kana, English, and romanized forms correspond, and where alternative or former names exist, leaving variation unresolved invites misreading the molecule as something else. The foreword warns not only against falsehood. A misleading manner of writing is to be avoided with equal weight. Notation of names is where that prevention pays off most cheaply.

04Chemical name and structure — fixing it to one point

The chemical name is written in the shared grammar of naming rules. For that reason the same molecule arrives at the same name the world over, without confusing salt, ester, hydrate, or optical isomer. The structural formula renders this as a picture, showing at a glance the geometry and bonding that prose conveys poorly.

The structure underpins later understanding

Sites of metabolism, interactions, and stability toward light and heat all reduce, in the end, to structure. Showing the skeleton accurately here gives the reader a foothold when reading the pharmacokinetics or compatibility sections. The structural formula is not ornament; it is the reference point that makes the later clinical text intelligible.

05Nuclear physical properties of radiopharmaceuticals

For radioactive substances only, nuclear physical properties — half-life, type and energy of radiation, mode of decay — are stated. This follows from the special circumstance that such drugs cannot be handled safely on chemical identity alone.

• Half-life governs the timing from preparation to administration or imaging, and the estimate of residual radioactivity.
• Type and energy of radiation set the premises for exposure control and shielding.
• Mode of decay bears on the nuclides produced and the choice of measurement method.

What is unnecessary for ordinary drugs is added for radioactive substances. The recording of identity is not uniform; it places, without excess or shortfall, the facts required by the nature of the drug. That principle shows itself here.

06Do not create "same fact, different appearance"

The trap of scientific writing is less in stating falsehood than in selecting facts to manufacture an impression. Even in the identity field, leaning a name toward the brand, or omitting an unflattering alternative name, can make the same molecule wear a different face.

So what is asked of the writer here is not clever expression but exhaustive fixing: a name whose source can be traced, a structure that cannot be mistaken, a molecular formula settled down to its form (salt, hydrate). With these in place, the reader can verify independently.

07Where the text is silent, govern by the higher norm

The required elements are set, but no provision dictates every detail of notation or the precision of a diagram. The spirit of the foreword asks that, exactly in the unwritten territory, one govern oneself by the higher norm — accurate, fair, not misleading. In the identity field this comes down to a single point: keep the molecule in a state where the reader can independently identify and verify it. The writer's discretion is used not to arrange impressions but to raise verifiability.

→ Source page: (9) Physicochemical data on the active ingredient

(10) Pharmaceutical properties

The tenth item of the comprehensive product information summary, "pharmaceutical particulars," deals not with the properties of the drug itself but with how it behaves as a finished formulation: how stable it stays during storage, and what changes occur when it is mixed with other drugs, infusion fluids, or solvents. This is not a place to talk about efficacy, the way the clinical results or pharmacology sections do. What clinicians want here is something more basic. Can this drug be safely added to a drip? Does it discolor at room temperature? The unglamorous information that bears directly on day-to-day handling is the star of this section.

The discipline governing this section is among the clearest in the entire guide. Only "facts confirmed by testing" may be written. No evaluation, no endorsement, no reassurance of safety belongs here. Why such restraint? The reason becomes visible when you trace it back to the spirit of the foreword.

01What this section covers — stability and compatibility

Two broad categories may be recorded under pharmaceutical particulars. One is the stability of the formulation. The other is its compatibility, the changes that occur when it is combined with other drugs. In both cases, the basis is limited to test results. Not conjecture or generalities, but results actually observed under defined conditions, presented exactly as observed.

Stability information forms the foundation for judging "for how long and under what environment" the drug can be used. Compatibility information gives the reader the material to decide for themselves, at the infusion line or the point of admixture, whether a given combination should be avoided. Neither is a place for the company to hand down a conclusion. State the facts, and leave the judgment to healthcare professionals. That is the basic stance.

02Compatibility data must state the conditions and the counterpart

When compatibility test results are included, two things must always be made clear: the test conditions, and the names of the products examined.

Why are the conditions required? Compatibility outcomes change with temperature, concentration, time, pH, and light. If the conditions are hidden and only "no change" is written, the reader may wrongly conclude the drug is safe under any circumstance. In reality, only a certain temperature and a certain duration were verified. Adding the conditions is the act of correctly handing the reader the reach of the test: how far it guarantees, and from where it is unverified.

Specifying the products examined rests on the same thinking. Rather than lumping things together as "the such-and-such injection," show concretely which product was mixed. As discussed below, even when the active ingredient is identical, behavior can differ if the excipients differ.

Why "no change" without conditions is hazardous

Suppose a compatibility test with a certain drug was run up to 25°C for six hours, and no change was seen in appearance or content. If this is displayed merely as "no compatibility change," it leads the reader to picture safety even at 24 hours, or under high temperature. This is not a lie: there genuinely was no change up to 25°C and six hours. Yet the manner of presentation grants reassurance beyond the facts. The foreword's principle, that the duty not to deceive and the duty not to mislead are distinct, is made concrete right here.

03Results are limited to the "facts" of physicochemical change — no evaluative words

What may be written as a compatibility result is limited to the facts of physical and chemical change. The color changed, a precipitate formed, the content declined, no abnormality was seen in appearance — such observed facts may be written. But evaluative words such as "compatible" or "may be combined" cannot be used.

This line is one of the strictest prohibitions in the guide, and the reason runs deep. The moment "may be combined" is written, the meaning shifts from a report of observed fact to permission or recommendation for use by the company. Pharmaceutical particulars is not a place to approve efficacy or usage. The foreword's logic of "complementation," that the summary cannot exceed the approved content by even a single character, is at work here too. Whether two drugs may be combined is a clinical judgment that varies with conditions, patient, and route of administration, and must not be pre-empted by a display in this section.

Why a line is drawn between fact and evaluation

As a matter of scientific practice, observation (the data) and interpretation (the conclusion) sit on different layers. From the same data, the conclusion can differ depending on who interprets it and in what situation. The guide bars evaluative words to prevent the company from stepping into the interpretive layer and steering the reader's judgment. The "fairness and objectivity" that the basic considerations of Chapter 1 consistently demand, and the stance of "not leading toward a convenient conclusion," are concentrated in this small prohibition.

04Choosing the counterpart drug — consistency, contraindication, caution

There is discipline, too, in choosing which drug's compatibility test to present. The drug used as the counterpart must be consistent with the product's dosage and administration and with its precautionary information. Lining up test results for combinations that are not actually expected in practice, or that contradict the precautionary information, only confuses the field further.

A particularly weighty prohibition is this: do not include compatibility test results with drugs that are contraindicated for concomitant use. A contraindicated combination is one defined in the precautionary information as one that "must not be used together." Placing compatibility data for such a drug in the summary, even as the physicochemical fact of "no change," would supply a false context suggesting the two might be combined. The display of the section must not conflict with contraindication, the highest-order safety provision.

For caution-combination drugs, note that fact alongside

For drugs that fall short of contraindication but require caution in concomitant use, including compatibility test results is not itself denied. However, the fact that the drug is subject to caution for concomitant use must be noted alongside. Even if no physicochemical change was seen, the information that caution is clinically required must not be left stranded outside the section. The fact of the compatibility change and the separate axis of cautionary information must be made joinable in the reader's own hands. This too is an implementation of the duty "not to mislead."

05Relationship to the standalone compatibility table

The compatibility content within pharmaceutical particulars is often expanded into a separate resource, the "compatibility change table." The two are run on continuous principles. In the compatibility table as well, the test conditions and the products examined must be stated, and results are confined to the facts of physicochemical change, with no evaluative words such as "compatible/incompatible."

If anything, the compatibility table demands these points more concretely: that even when the active ingredient is identical, other companies' products be recorded by trade name in view of excipient effects; that compatibility data with contraindicated-combination drugs not be included; and that caution-combination drugs be noted as such. The pharmaceutical particulars section is also the entry point that leads to this more detailed resource.

06Connection to the spirit of the foreword

Pharmaceutical particulars may look like a plain section, far removed from showy claims of efficacy. Yet it is also where the design philosophy of the guide appears most plainly. Show only the facts and add no evaluation; state the conditions and the counterpart so as not to misrepresent the reach; do not conflict with contraindication, the higher-order provision. Each of these converges on a single point: the product information summary is a "complement" to the package insert and does not exceed the approved content.

Hand over the information needed to handle the drug safely and appropriately, with neither exaggeration nor omission. Before speaking of efficacy, first make it possible to handle the drug correctly. What this section embodies is the very order that runs through the whole guide: a tool for using the drug safely comes before a tool for selling it.

→ Source page: (10) Pharmaceutical properties

(11) Handling precautions

Before a product reaches the patient it travels a long path: manufacturing, shipment, distribution, storage on the ward, dispensing, administration. If the cold chain breaks along the way, if the product is exposed to light, if the expiry date passes, or if one product is mistaken for another, even the most carefully designed efficacy and safety can be cancelled out. Item ⑪, "Precautions for Handling," supports the quality and traceability that must hold right up to the moment of use. What it governs is not the size of a treatment effect, but the conditions for delivering the product in the right state and the right way.

As the foreword establishes, the electronic package insert is the authoritative record of what the product is. It must not merely exclude wrong information; it must also prevent misunderstanding in practice. Vague wording on storage or expiry is itself a breeding ground for misunderstanding. Handling precautions are unglamorous, but they bind the decisions clinicians make at the bedside, and they are not a section to treat lightly.

01What to write, and how far

The basis for a statement varies in strength. For products where precautions for handling are fixed by the pharmacopoeia, by official standards, or as a condition of approval, those defined precautions must at least be stated. This is not optional; it is a floor. For products with no such official requirement, anything that genuinely warrants caution in handling should still be recorded if it exists.

This structure—"the official requirement is the floor, real-world facts are the addition"—maps onto the spirit of the foreword. Even where there is no explicit rule, a higher norm (protecting the patient, avoiding misunderstanding) governs what must be written. The line is not drawn by whether the pharmacopoeia happens to mention it, but by whether the field would be in trouble without the information.

02Breaking it into sub-headings

Because handling information mixes items of different natures, it should not be lumped together but separated into sub-headings. The typical sub-headings are as follows.

• Precautions for handling — concrete cautions for storage, preparation, and administration, such as handling after opening, incompatibilities, light protection, or "do not invert."
• Storage — the conditions, such as temperature and light protection, needed to preserve quality.
• Shelf life — the period over which quality is maintained when stored under the specified conditions.
• Use-by date — the date after which the product should not be used.

Separating them lets the reader reach the needed information by the shortest route. A layout that forces a pharmacist looking for storage conditions to hunt through descriptions of incompatibilities invites both misunderstanding and oversight.

Do not confuse "shelf life" with "use-by date"

The two are similar but not the same. Shelf life is "the period over which quality is maintained if stored under the specified conditions"; the use-by date is the operational boundary of "do not use after this day." Their meaning as labelling and their handling in the field both differ, so they must not be casually interchanged.

03Records and retention for specified biological products

For specified biological products that use raw materials derived from humans or animals, handling precautions go beyond storage conditions. The backbone of safety here is the ability to trace, after the fact, which product was used in which patient should a material-derived problem come to light years later. To that end, the insert states—following the electronic package insert—the items to be recorded at the time of use and how those records are to be retained.

The items to record include the brand name, the manufacturing number (lot number), the date of use, and the name and address of the patient who received it. And it states that these records should be retained for at least 20 years.

Why a span as long as 20 years

Twenty years is no small period. It reflects the scientific recognition that infectious risk associated with biological raw materials may surface only after a long latency following administration. If the records are already lost by the time a problem is identified, neither a traceback investigation nor patient notification is possible. Record retention is a measure that secures the precondition for future safety action, even when it appears to serve no purpose at the moment it is made.

04Aware that the wording binds the field

Unlike an abstract account of efficacy, the statements in this section directly determine the hands-on actions of pharmacists and nurses. Write "protect from light" and it will be protected; write "store at room temperature" and it will not be refrigerated. Precisely for that reason, conditions must be written concretely—including ranges and premises—leaving no ambiguity.

The same fact gives the field a different impression depending on how it is written. Push the date to the front and let storage conditions recede, and the storage conditions are treated lightly. The editorial decision of which information to place at equal weight is itself part of writing that avoids misunderstanding.

→ Source page: (11) Handling precautions

(12) Packaging

Within a product information summary, "packaging" looks like a minor entry. Compared with efficacy or dosage, there is little to write. Yet the accuracy of this single line underpins the whole path a medicine travels — being handed over, shelved, dispensed, and finally reaching the patient. What the creation guide asks for here is not elaborate prose. It is simply this: state, completely and without excess, the units in which the product is packaged and distributed. That is all. But underestimate "that is all," and the result on the floor is mix-ups — errors that reach the patient directly.

01What to write —— packaging units as practical information

The packaging entry records the packaging units of the product as sold. For tablets, how many tablets per sheet and how many sheets per box; for injectables, how many ampoules or vials per pack; for oral liquids, the bottle volume. Write it at a granularity that lets the reader identify, without hesitation, exactly which package they are using.

Seen through the spirit set out in the foreword, the product information summary is a document that complements the electronic package insert — it is not the original. The packaging description does not escape that relationship. Two things decide whether this entry is done well: that it does not contradict the packaging information fixed in the electronic insert, and that it leaves the reader no room for stray interpretation. The shorter the entry, the more the writer's discipline shows.

02Why write it —— preventing mix-ups and securing reliable distribution

Packaging information carries two main practical values. One is smoother distribution. Ordering, delivery, and inventory all move against packaging units. When the description is vague, the floor spends time on inquiries and confirmations. The other is prevention of mix-ups. When products of different strengths or different packs sit on the same shelf, a clearly stated packaging unit becomes the last line of defense.

Mix-ups are born from "misunderstanding"

One of the principles the foreword raises is to write not only without falsehood but without breeding misunderstanding. The packaging entry is a miniature of this principle. Even if the figure written is true, if the reader confuses it with another package, the result is no different from an accident. Being factual and being free of misreading are separate requirements. The packaging description must satisfy both at once.

Govern unwritten areas by higher norms

There is no clause specifying packaging wording down to the last detail. But the absence of explicit rules does not mean one may write freely. Following the foreword's spirit, areas the rules do not reach are governed by higher principles — accuracy, avoidance of misperception, consistency with the electronic insert. The packaging entry becomes exactly the training ground for "filling unwritten areas with discipline."

03Details —— judgments for the easily confused cases

Packaging is a short entry, but in practice a few situations call for judgment. Here are the representative ones.

When multiple packaging units exist

If a single product comes in several packaging units, list every one without omission. Writing only some risks letting the reader assume "this is the only one." Completeness here ties directly to avoiding misunderstanding.

When touching on differences in packaging form

If several forms exist — PTP sheets, bulk packaging, unit-dose packs — show the unit for each. Because form affects how a medicine is dispensed and stored, present it alongside the unit so the reader can judge.

Consistency with the electronic insert

Packaging information also appears in the electronic package insert. The description in the product information summary must not diverge from the insert, which is the original. When a revision changes the packaging, do not forget to have the summary follow suit. Make the consistency check a habit — the last small step after writing.

→ Source page: (12) Packaging

(13) Related information

"Related information," the thirteenth item of a comprehensive product information summary, is unglamorous, yet it mirrors the character of the Creation Guide well. Unlike efficacy or clinical data, it does not draw the reader in. It records, in dates and numbers, when a product passed through which public procedures and where it now stands: the approval number, the approval date, listing on the drug price standard, the start of marketing, any conditions attached to approval, matters concerning insurance reimbursement, and the milestones of re-examination and reevaluation. None of these are things a company narrates freely. They move according to regulatory judgment and official notice. Whether this section can be written accurately is a touchstone for whether the entire material is "built to be verifiable."

01Why bother listing "dates and numbers"

Much of related information looks like a string of figures. But the intent of placing the date of preparation or revision as the closing item, with this section just before it, is clear: to let the reader cross-check facts afterward — that is, to guarantee verifiability through structure. An approval number can be matched against the official notice. An approval date lets one trace which indications were recognized at that point. The dates of price listing and marketing start say whether the product is actually usable in clinical practice.

The integrity of this section shows not only in the correctness of the figures written but also in how unwritten items are handled. The Creation Guide asks that, where no applicable information exists, the item heading itself be omitted. Leaving a blank with only "none" to hint at existence, or making something undetermined look settled, may not breach the duty not to lie, but it does collide with the duty not to mislead. A section that looks free of the temptation to "present things favorably" in fact tests integrity on both sides — omission and commission.

02Writing the approval number and date correctly

The approval number and date are the core of the fact that the product obtained approval under the Pharmaceuticals and Medical Devices Act. For products where indications were added later, the dates of those additional approvals are recorded up to the most recent one. Listing only the first approval date and saying nothing of later additions misrepresents where the product now stands.

For drugs that do not require approval, the marketing business license number is recorded in place of the approval number. The international birth date is supplementary information that may be appended when needed.

How far to follow additional approvals

For products whose indications were added more than once, the phrase "up to the most recent" carries weight. Keeping only the old approval date and omitting the latest indication addition may lead the reader to mistake that indication as still off-label. Conversely, lining up unapproved indications under application as if approved is not permitted either. The approval date must be accurate as a mirror reflecting the approved scope at that moment.

03Handling the drug price listing date

The date of listing on the drug price standard bears directly on whether the product can be used under insured care. If not yet listed, that fact is stated. At the new-launch stage the listing date may not be settled; in that case the practice of showing only "listed on the drug price standard" and entering the confirmed date at reprinting is permitted.

When a unit price is given, the date of listing or revision is shown alongside it. Because drug prices move with revisions, a unit price without a date leaves the reader unable to tell as of when the price holds, and thus misleads.

04Marketing start date and conditions of approval

The marketing start date may be left blank at new launch or when the timing is undetermined, with the confirmed date entered at reprinting. Where it is genuinely unknown, "unknown" is written. Here too the principle holds: do not present the undetermined as settled.

Conditions of approval are written according to the electronic package insert. If there is no information on a condition, that item heading is not written at all. A summary is acceptable as long as the content is unchanged, but the summary must not distort the intent of the condition.

What "omit the item entirely" means

When applicable information is absent, the Guide steers writers away from leaving the heading with an empty body. An empty heading raises the reader's expectation that "something should be here," and so produces a false impression. If there is no information, do not place the item at all. This is the foreword's concern — that a single way of presenting can breed misunderstanding — made concrete in the quietest of sections.

05Matters concerning insurance reimbursement

Under matters concerning insurance reimbursement, one records that the product is outside reimbursement, or only partly covered, or information on drugs subject to dosing-period limits. This is practical information on a different axis from efficacy or safety — it shapes how the product can actually be used. Failing to convey the scope of reimbursement accurately risks prescribing decisions in the field diverging from fact. For products to which this does not apply, the item is not set up.

06Re-examination and reevaluation as a time axis

A drug's evaluation does not end at approval. Re-examination is conducted in light of post-marketing use, and reevaluation is applied as needed. Related information records the milestones of this time axis too.

When a re-examination period expires, its expiry date is recorded; when re-examination results are published, that publication date is recorded. For products whose re-examination period differs by indication, the expiry date and the number of years of the period are shown for each indication. Results are recorded as the most recent ones. The publication date of reevaluation results is likewise recorded as the most recent, but reevaluation concerning quality need not be recorded.

Why quality reevaluation is excluded

That reevaluation concerning quality is left out of the recording scope can be read as following from this section's purpose: to let healthcare professionals trace the current state of efficacy and safety evaluation. Quality reevaluation is a procedure on the manufacturing-control side, different in character from the evaluation axis that bears directly on prescribing decisions. Even the line between what is recorded and what is not reflects the section's intent.

→ Source page: (13) Related information

(14) Key references

The sixteen items of the comprehensive product information summary open with the development story, pass through the clinical results that form the core of efficacy, and close with the location of the evidence and the marking of the version. One of the two closing pillars is this item ⑭, Main References. There is no dramatic prohibition here. The task is simply to list, in a form anyone can later trace, the references that support the text. Yet this unassuming list is the keystone that turns the document's claims into claims that can be verified.

01Why "just listing references" earns its own item

The foreword places on companies a duty to convey accurate information, and at the same time positions the product information summary as a "supplement" to the electronic package insert. Being a supplement, its contents may not step beyond the scope of approval, and must also be in a state where a third party can confirm whether they are correct. The means of confirmation is precisely the source. A claim whose source is not shown offers the reader no entry point for verification, even if its content is true.

The third of the design principles that run through the Creation Guide — securing verifiability through structure — takes concrete form here. Citing sources, disclosing statistical methods, marking the date of preparation or revision: these look like separate rules, but their aim is one. To place into the reader's hands the answer to "what is this statement based on?" The references section is where that handover is performed all at once, in the shape of a list.

02The weight of an obvious act: listing the supporting references

What goes into the references is the literature that supports the statements in the text. Not academically impressive papers added for decoration, nor loosely related reviews used to borrow authority. Only references with which the body's statements on efficacy, safety, pharmacokinetics, and pharmacology can each be matched to their foundation earn a place here.

This condition — that the correspondence holds — is continuous with the discipline of the evidence hierarchy. Meta-analyses and randomized controlled trials, observational studies, case reports, and expert opinion carry vastly different weight of conclusion. Whether peer review was undergone is the watershed of quality. What is listed in the references implicitly discloses on which tier of evidence the text's claims rest. By looking at the nature of the sources, the reader can judge how strongly to take each statement.

What the nature of a source tells the reader about how strong the evidence is

For the very same statement that something "works," the certainty a reader should assign differs by orders of magnitude depending on whether the support is an original randomized controlled trial, a case report of a handful of patients, or a review that never left the company. The reference list is not a bare roll call of sources; it is itself the information that hands the reader the confidence level of each claim.

• Peer-reviewed original papers — published and subjected to critical examination by third parties. The easiest to trace, with the clearest character.
• Approval-time evaluation materials — primary material the regulatory authority used in its approval decision, publicly scrutinized through a route separate from publication.
• Case reports and expert opinion — strongly individual, calling for caution before generalization. Listing them is not barred, but they must not be made to look like strong evidence.

03When the clinical results are approval-time evaluation materials

When the basis of the clinical results is material that was evaluated during the domestic approval review process, this fact is stated explicitly in the references. Approval-time evaluation material is the primary material the regulatory authority used in its decision to approve, and ranks among the heaviest of sources. That is exactly why writing "this rests on material evaluated at approval" carries meaning. The reader learns that the statement underwent public scrutiny through a route distinct from whether it was ever published as a paper.

04Bibliographic details on the clinical results page too — why place them twice

References relating to clinical results are not only gathered in the references section at the end; their bibliographic details are also recorded on the very page of the relevant clinical results. At first glance this is duplication, but it is intended doubling, not redundancy.

The reason lies in the reader's path. The moment a reader looking at a clinical-results figure wonders "what is this based on?", if the source cannot be confirmed on the spot, the flow of verification breaks. Going back to the end, then re-matching the body's claim against the list, is effort that pushes confirmation away. With the bibliographic details right beside the data, claim and evidence sit within the same field of view. Verifiability is not enough as "confirmable in principle"; it works only when designed to the point of being "easy to confirm in reality."

05When the source is internal company material

Sometimes the basis is neither a peer-reviewed original paper nor approval-time evaluation material, but internal company material. What the Guide demands then is not to stop at writing "internal material" as the source name. The specific content of that material must be recorded so that it can be understood.

Behind this lies the fact that there is a step in the verifiability of sources. Published papers can be traced to the original by anyone. Approval-time material has passed public evaluation. Internal material has neither form of openness. Because it is hard for the reader to obtain the original directly and confirm it, at the very least one adds enough specificity to trace "what was measured, in what subjects, and how." This is not a rule that excludes internal material; it is a brake that keeps weakly verifiable material from passing through opaquely while still weak.

The specificity to secure when citing internal material

• The subjects and conditions the material addresses must be readable. The four characters "internal material" alone support nothing.
• It must be traceable which statement in the text the internal material corresponds to. A source whose correspondence cannot be traced is a blank dressed as a source.
• It must not be presented as if it were "strong evidence" on par with published literature. Not misrepresenting the nature of the source is part of the duty not to mislead.

06What it secures paired with ⑯ the date of preparation or revision

Main references (⑭) show "what it rests on"; the date of preparation or revision (⑯) shows "as of when the information stands." It is no accident that these two stand at the end of the sixteen items. The location of the evidence, and the point in time of the version. Only when these two are together can the reader grasp, in complete form, "as of when, and on what basis, this material stands."

→ Source page: (14) Key references

(15) Marketing authorization holder

Among the sixteen items that make up a comprehensive product information summary, item ⑮ covers the "name and address of the marketing authorization holder." It looks like a plain contact box, but the spirit of the foreword lives here in concrete form. Every individual claim made in a piece of material ultimately leads back to a single question: who is accountable, and where can a reader go to check it? Marking that location is the job of this item.

01What is recorded — the responsible party and the address

What is written here is the name and address of the company that markets the drug. For a corporation, the address is the location of the office where the marketing supervisor-general carries out their duties — not merely the registered headquarters, but the place where the person who oversees quality and safety management actually works. This matters because, under the Pharmaceuticals and Medical Devices Act, ultimate responsibility for marketing rests with the marketing authorization holder, and the marketing supervisor-general is at the center of that responsibility. The address field should be read as a declaration: "the working base that bears final responsibility for the quality of this information is here."

For products involving several companies — a launching company, a distributor, an allied partner — each may be listed together. With prescription drugs it is not unusual for the marketing authorization holder and the company that handles sales to differ, or for several firms to appear because of in-licensing or partnership arrangements. So that readers do not mistake "which is the contact point" or "who is the responsible party," related companies are permitted to be shown side by side.

02Why specify the address at all

If a company name alone were enough, an advertising credit would suffice. The reason the Creation Guide insists on the address, and pins it specifically to the office of the marketing supervisor-general, is that it treats this box not as decoration but as the "location of responsibility." Inquiries about safety information, reports of adverse reactions, confirmation of references — none of these work unless there is a real, reachable destination. The foreword's "duty to convey accurate information to healthcare professionals" is only complete when there is a receiving point ready to take inquiries after the information has been conveyed.

03The case of a foreign special-approval holder

For a drug where an overseas company holds the approval as a foreign special-approval holder, the requirement grows one step heavier. In addition to the name and address of the designated marketing company that handles operations domestically, the name of the foreign special-approval holder and the country in which its address is located must also be written.

The reason lies in a two-layer structure of responsibility. The overseas entity that holds the approval in its name and the designated company that carries domestic marketing responsibility and serves as the contact point are different bodies; for a healthcare professional, the domestic designated company is the realistic first port of call. At the same time, knowing which country the entity holding the approval belongs to is indispensable for understanding the product's origin and where final responsibility ultimately rests. By showing both the domestic window and the overseas approval-holder, it becomes clear both whom to contact and who bears final responsibility.

How the designated marketer and the approval holder differ in role

04Literature-request and inquiry contacts

This item also records the literature-request contact and the inquiry contact. Even when ⑭ Principal References shows where the basis lies, it cannot be called "verifiable" unless there is a destination from which that literature can actually be requested. The reason a responsible department and its contact details may be listed alongside is that reaching the section that actually handles the documents directly is more effective for inquiries than going through the company's general window.

Connection to the "upon request" spirit

Throughout the Guide, material such as article reprints and abstract collections must be provided in response to a healthcare professional's request, not pushed. Clearly stating the inquiry and literature-request contacts is also the entrance that makes that "upon request" relationship possible. Rather than a company delivering one-sidedly, it prepares a route by which professionals who need the information can come to confirm it themselves — listing the contact serves, as a matter of structure, to support that receptive posture.

→ Source page: (15) Marketing authorization holder

(16) Date of preparation or revision

01Date of Preparation or Revision — The Quiet Promise of Recording the Edition

Print the year and month the material was prepared, or the year and month it was revised, in a visible place such as the front or back cover. Among the many items the guidance lists, this single line placed sixteenth is so quiet that, reading the heading alone, you might pass right over it. Yet this item mirrors the character of the whole guidance better than any other.

It is not a showy prohibition. It differs in kind from the assertive rules that say "do not write this" or "do not exaggerate that." All it asks is that you leave one line of history: when this was made, and when it was changed. That is all. But the accumulation of such plain acts is exactly what supports trust in a material from the ground up.

Why a Mere "Year and Month" Carries Such Weight

It makes sense once you return to the spirit of the foreword. The electronic package insert is the original; promotional materials stand in a supplementary role to it. The original gets revised — an indication is added, dosage is reconsidered, occasionally a serious adverse reaction is newly written in. When the original moves, the material that copied from it grows stale too.

At that moment, if the material bears no date of preparation or revision, the reader cannot judge "as of when does the booklet in my hands speak?" Was it updated against the new package insert, or does it still carry the old wording from before the revision? That one line of date is the minimal clue that makes such a judgment possible.

Securing Verifiability by Structure

At the root of the guidance lies a stance of avoiding not only falsehood but misunderstanding. Recording the date is the practical expression of that stance. When someone later tries to verify a material — in an audit, a self-inspection, or a recall decision — verification cannot even begin if "which edition" is unknown.

In science, an experimental record without a date can be neither reproduced nor re-tested. Evidence cannot be divorced from "when and under what conditions it was obtained." A material is the same: a sheet lacking the attribute of a date shuts the door on verification by its own hand.

02Putting It Into Practice — The Fine Print and Common Slips

Once the intent sinks in, the next task is to turn it into a working procedure. From here we bring it down to specifics: where to write it, how to write it, and what not to overlook. The reasoning is spent in the first half. What remains is the routine that keeps you from repeating the same omission at every revision.

The Fine Print — Where and How to Write It

The place is defined as "somewhere visible." This is not merely about appearance. When a recall or replacement becomes necessary, it matters that the person holding the material can flip it over and check the date at once. Placing it in a visible spot on the front or back cover serves the intent better than tucking it small at the bottom of a colophon.

• On preparation — record the year and month the first edition was released.
• On revision — update to the year and month of the change. Leaving the old date in place hides the fact that a revision occurred.
• Position — the front or back cover, or similar, where a reader can reach it without hunting.

The Relation Between "Date" and "Edition" — What Are We Trying to Distinguish?

Governing the Unwritten by Higher Norms

The guidance does not bind the date format word for word. Calendar style, how finely to record it — such details are left to discretion. But "left to discretion" does not mean "anything goes." As the foreword teaches, even unwritten territory is governed by a higher norm: the purpose of keeping the reader able to judge correctly. When in doubt about how to write the date, choose by one standard — whether that line will withstand later verification.

→ Source page: (16) Date of preparation or revision

Chapter 3: Specific-Item Product Information Summary

If the comprehensive product information summary paints the full picture of a single drug, leaving nothing out, then the specific-item product information summary is a single cross-section sliced from that picture. An explanation of a feature, a mechanism of action, clinical results, a particular indication or dosage—when the point you want to make is already settled, you build around that one item instead of laying out all sixteen sections. Chapter 3 governs this "narrowed-down" way of building a resource.

Yet narrowing the focus and skipping the foundation are two different things. The first guardrail, placed at the very top of Chapter 3, says exactly this: even a specific-item version must comply with the basic considerations of Chapter 1 and with the relevant item provisions of Chapter 2. Restricting scope does not create freedom from the three disciplines—scientific grounding, the balance of efficacy and safety, and the bounds of approval.

01What counts as a "specific item"

A specific-item product information summary is one whose content is limited to particular items: an explanation of a feature, a mechanism of action, clinical results, an indication, a dosage. Where the comprehensive version runs through everything from the product's identity to its supporting references and revision date, this one fixes on a single theme and writes carefully only around it.

In character it is close to a subset of the comprehensive version. Precisely for that reason, care is needed so that showing only a part does not mislead about the whole. A resource that extracts only clinical results, with a thin treatment of safety, can leave an impression skewed toward efficacy. Many of Chapter 3's provisions exist to curb this "bias born of partial presentation."

Relationship with Chapters 1 and 2

The specific-item version is not a separate, independent line of resource; it lives inside the same normative system as the comprehensive version. It must satisfy Chapter 1 (the foundation that applies to all resources) and also follow the Chapter 2 item provisions corresponding to the items it handles. If it carries clinical results, for example, the requirements imposed by Chapter 2's clinical-results item—stating the trial design, distinguishing confirmatory analyses from nominal p-values, attaching the source—remain in force unchanged.

02Mandatory items—the core you cannot drop even when narrowing

Narrowing the items does not license deleting information essential for safe use. Chapter 3 sets out the mandatory items to be carried whatever the theme. The key point is that the information identifying the product, the substance of the approval, and the framework of safety are all present together.

• Information identifying the product—classification number, therapeutic category name, regulatory class, name, and whether it is listed in the drug price standard
• The most important safety frame—warnings and contraindications
• The product's makeup—composition and properties
• The substance of the approval—indications (with related precautions) and dosage and administration (with related precautions)
• The system of precautions for use—important basic precautions, precautions for patients with specific backgrounds, interactions, adverse reactions, effects on clinical test results, overdose, precautions concerning application, and other precautions
• Practical information—precautions on handling, packaging, related information
• Accountability and version—the marketing authorization holder and the date of preparation or revision

Reading the order, it begins with the product's identity, brackets the bounds of approval, passes through the system of precautions, and closes with "who made it" and "which version." The same design philosophy as the comprehensive version—closing with the grounds and the version so that later verification is structurally guaranteed—runs through the condensed version too.

Conditions when consolidating mandatory items into the DI

The mandatory items may also be consolidated together in the product information (DI) section. This is a practical accommodation for organizing the page, but it is not unconditional. When consolidated, the resource must also state that "the details are to be found in the package insert" and that "attention should be paid to revisions of the package insert."

Type in the DI section, figures and tables aside, must be at least 6 points. This is a floor that prevents "counting as carried" mandatory information that has been compressed to an unreadable size.

03The cover—placing the most important information in the first field of view

The cover's items are handled as in the comprehensive version. The cover is the face of the resource, the surface a reader sees first. For that very reason, its appearance is regulated down to detail so that the most important safety information falls within the first field of view.

How warnings and contraindications are shown

Warnings and contraindications are placed on the cover in gothic type of at least 10 points, clearly. Specifying the typeface and point size is the foreword's "convey accurately, without misleading" translated into physical layout. Merely being written is not enough. Unless it enters the eye first and reliably, the safety information has not been conveyed.

The unified mark in the first six months after launch

A new drug subject to early post-marketing phase vigilance carries the unified mark on its cover for the first six months after launch. In the period soon after reaching the market, the safety profile is still accumulating, and the mark signals that uncertainty to the reader.

04Safety and the honesty of data

Precisely because the narrowed-down form often pushes clinical results or features to the front, clear guardrails are placed on how safety is handled.

The type size of safety

Statements about safety are set in type the same size as, or larger than, the body text for efficacy. Efficacy must not outweigh safety in the physical size of the type—the asymmetric care that "if you speak of efficacy, you must show safety at least as prominently" is again implemented here as layout.

How primary endpoints are shown

In a trial that set a primary endpoint, its result is set in the same typeface and the same type size as the result of the secondary endpoints. At a glance this is a matter of technical formatting, but the aim is to shut down impression management. If typeface or size differed between primary and secondary, results that should not be read as ranked could be ranked for the reader by visual emphasis.

05Isolating reference information

Reference information—results obtained secondarily within the approved range, or pharmacological actions that underpin an indication—is constrained in placement and in volume so that it does not blend, in the reader's mind, with the genuine approval information. Chapter 3 guards this distinction with three concrete fences.

Why it is kept off the cover

Reference information is barred from the cover and the pages following it because the first information a reader meets must be the authoritative text of the approval. If a secondary result or a pharmacological action of unclear relevance adorns the opening, it gets misread as the product's principal selling point. The opening is a place for approval information; reference information goes behind it, in a clearly distinguished form.

Why the limit is one quarter

Holding the volume to within a quarter of the page, excluding the cover and DI, prevents the resource as a whole from being padded out with reference information so that "reinforcing material" overshadows the facts of the approval. Reference information is a supporting role to the end and cannot become the lead on the page—the volume cap guarantees that division of roles.

Why no supervisor's comment

Attaching a supervisor's comment to reference information would lend a third party's authority to what is merely a supplement, giving it weight equal to or greater than the approval information. Reference information must not be promoted by borrowed authority—the ban on comments is the fence for that.

→ Source page: Chapter 3: Specific-Item Product Information Summary